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Abstract 
Epidermal growth factor receptor (EGFR) is a transmembrane receptor tyrosine 
kinase that involved in many critical cellular processes. Abnormal expression of 
EGFR or its downstream signaling components is a common phenomenon detected in 
many types of human cancers. Recently, EGFR and its downstream signal molecules 
become exciting targets in cancer therapy. However, due to the highly complexity of 
the EGFR signaling network, further understanding about the therapeutic use of 
targeting EGFR signaling will be essential. 
In the present study, the human squamous carcinoma A431 cells, including A431 
parent cells and EGF-conditioned cells which were established by prolonged 
incubation of cells with 50ng/ml EGF, were employed. EGF suppressed the growth of 
A431 parent cells but stimulated the growth of EGF-conditioned cells. Furthermore, 
the expression levels of a number of critical signaling molecules involved in EGFR 
signaling (including the Ras/Raf/MAPK pathway, the Jak/Stat pathway and the 
PBK/Akt pathway) were also found to be different in two cell lines. The results 
suggested that the EGFR signaling in EGF-conditioned cells may be altered. By the 
use of modifiers targeting different parts of EGFR signaling pathways, it was 
suggested that the EGF growth inhibitory effect in A431 parent cells is believed to be 
the Ras/Raf/MAPK pathway related and the stimulation effect in EGF-conditioned 
cells is the Jak/Stat pathway related. 
In addition to EGF growth responses, the sensitivity pattern of A431 parent cells 
and EGF-conditioned cells to a series of common anticancer agents were also studied. 
Compared to A431 parent cells, EGF-conditioned cells were more resistant to 
camptothecin, methotrexate, vincristine and taxol, but less resistant to 5-fluorouracil 
and shown similar drug sensitivity to cisplatin and ionizing radiation. The underlying 
V 
mechanisms contributed to the differential drug sensitivity in two cell lines were 
further examined by studying the expression levels of various classical drug resistant 
factors and drug-induced apoptosis. Camptothecin-mediated resistance seemed to be 
related to its classical drug resistance target, topoisomerase I. Also, in 
5 -fluorouracil-mediated resistance, it was correlated with its three classical drug 
resistance targets, including thymidylate synthase, dihydropyrimidine dehydrogenase 
and thymidine phosphorylase and drug-induced apoptosis respectively. For the 
other anti-cancer drugs, the inter-relationship between their differential drug 
sensitivity and the alteration of EGFR signaling in EGF-conditioned cells were 
indicated by studying the influence of the EGFR signaling modifiers on drug 
sensitivity on cells. 
Further investigation of the inter-relationship between the differential EGF 
related growth responses, drug sensitivity and the alteration of EGFR signaling due to 





















有絲分裂原激活蛋白激酶系統路徑一 the Ras/Rat/MAPK pathway ；激酶結構連接 
蛋白及激活訊息傳導和轉錄激動子系統路徑一the Jak/Akt pathway及磷酯酸肌醇 
3—激酶系統路徑一the P13K/Akt pathway)中的關鍵分子，可發現它們的水平在兩 
種不同的A431細胞中有不一樣的表達模式。由此可見，EGF條件化A431細胞 
中的EGFR訊息傳導路徑可能已經改變。所以接着利用一連串相應的訊息調節劑 











是與去氧核糖酸拓補導構酶I(DNA topoisomerase I)有關。與此同時，在EGF條 
件化A431細胞中所引致的對5-Fu的抗藥性亦相信是與它三個典型抗藥性因子 
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According to the statistics from Hong Kong Hospital Authority, cancer is the first 
killer suffering lots of people in Hong Kong and all over the world. Moreover, in 
Hong Kong, the number of the cancer incidence is growing and growing every year. 
{Figure LI). Therefore, it is a must for us to pay attention to it. 
In multi-cellular organisms, cells have a complex and elegant system for the cells 
to communicate and co-ordinate with different cells so that cells are able to respond to 
internal and external signals to regulate their growth and death. However, cancer cells 
can escape from this regulation and exhibit uncontrolled cell growth during 
carcinogenesis�Thus, cancer cells are highly dependent upon either the host-derived 
or endogenously-produced peptide growth factor for their proliferation and cell 
survival In fact, the uncontrolled cell growth is multi-factorial. {Bishop, 1987; 
Fcaron and Vogclstcm, 1990). It is caused by combination of various factors, 
including activation of particular oncogenes, loss of expression or mutation of tumor 
suppressor genes. Especially, elevated expression of growth factors, growth factor 
receptors or other proteins involved in the intracellular signal transduction are critical 
factors for carcinogenesis induction. (Liotta and Liu, 2001) 
1 
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1.2 Growth Factors 
Growth factors belong to a large diverse group of polypeptides that have 
common property of inducing cell proliferation both in vivo and in vitro. Moreover, 
they can act as a messenger within the cell to coordinate with specific receptors to 
regulate a lot of critical ongoing biological processes. It can stimulate cell growth, 
promote tissue growth during embryonic development, wound repair and tissue 
regeneration in the adult. Growth factor can be grouped into "families" of molecules 
with related structures and sequences, including the platelet-derived growth factor 
(PDGF) family, the epidermal growth factor (EGF) family, the fibroblast growth 
factor (FGF) family, the transforming growth factor (TGF) family, etc. Besides, they 
can exert their biological effect at very low concentration 
2 
physiologically. 
Growth factors and endocrine hormones share many common properties. 
However, growth factors are different from endocrine hormones, such as growth 
hormone. First of all, growth factors are usually synthesized in various types of cells 
and tissues. But, for endocrine hormones, they can only be synthesized in specialized 
glands, for example, pituitary is mainly specific for growth hormone synthesis. Apart 
from this, growth factors mainly act locally within the tissues in which they are 
synthesized. Not like endocrine hormones, they are released into body fluids at the 
synthesis site and then carried to their corresponding remote target tissues through 
bloodstream. Growth factors can exhibit their actions by a few mechanisms, including 
autocrine, intracrine, paracrine, juxtacrine or endocrine. Autocrine represents when a 
growth factor is secreted and acts upon the same cell. Intracrine interaction represents 
when a growth factor is secreted and acts within a cell. Paracrine represents when a 
growth factor is secreted by a cell and it then interacts with the neighboring 
‘responsive cells in very close vicinity. Juxtacrine stimulation represents when one cell 
has surface bound growth factor that interacts with an adjacent cell containing growth 
factor receptor. Endocrine represents when a growth factor carried through the blood 
stream and then acts on some distant cells. {Figure 1,2). In addition, another critical 
characteristic of growth factor activity is that they exhibit cell-type specificity in their 
3 
actions. Some cell types can respond to a series of various growth factors; however， 
others are highly restricted for particular growth factors only. 
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1.3 Growth Factor and Growth Factor Receptor 
As mention before, growth factor and growth factor receptor involved in many 
important physiological role in the normal process of growth and differentiation. 
Following the binding of the growth factor to its corresponding receptors, it induces 
conformational changes and then leads to receptor dimerization and cross 
phosphorylation so that the receptor becomes activated. The activated receptor can 
then phosphorylate and activate a series of different cytoplasmic proteins that in turn 
initiate a cascade of signal transduction to lead to the activation of transcription 
factors in the nucleus so that mRNA synthesis is increased. Finally, increased protein 
4 
expression can lead to either growth or differentiation. {Fantl et al, 1993). 
Although growth factor and its receptors play a critical role in many 
physiological processes, however, deregulation of the functions and expression of 
these molecules and components lead to various neoplastic and non-neoplastic 
diseases. For example, loss of function by mutation in growth factor receptor can lead 
to inherited diseases, such as insulin-resistant diabetes (insulin receptor) (Accili et al, 
1989) and dwarfism (Achondroplasia) (Fibroblast growth factor receptor 3 --- FGFR 
3). (Shiang et al, 1994). Over-expression of growth factor can lead to non-neoplastic 
diseases, such as psoriasis (TGF-a). {Elder et al, 1989). Especially, aberration in 
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Alteration of EGF Responses and 
EGFR Signaling in 
EGF-conditioned A431 Cells 
2.1 Background Information 
2.1.1 Epidermal Growth Factor (EGF) 
Epidermal growth factor (EGF) is one of the important and widely studied 
growth factor. EGF is a single polypeptide chain that containing 53 amino acid 
residues ( � 6 kDa). {Figure 2,1). EGF was the first growth factor to be obtained in 
pure form and it was first separated from nerve growth-promoting substances by 
Stanley Cohen in 1960 {Cohen, 1960) that led to the recognition of tissue-specific 
factors that were critical for the process of cell growth and repair. After that, in 1962, 
Cohen injected purified EGF into newborn mice that can result in precocious eyelid 
opening and eruption of incisor teeth. {Cohen, 1962). Therefore, it indicated that EGF 
is responsible for epidermal proliferation and differentiation. (Cohen and Elliott, 
1963). Later, due to the discovery of urogastrone from the urine of pregnant women 
that is now recognized as the human homolog of EGF could inhibit gastric acid 
secretion {Gregory, 1975) , it can demonstrate that EGF also participated in the 
regulation of other ongoing physioiogical events in addition to cell growth and 
division. 
Whereas, according to molecular cDNA cloning of human EGF genes, it reveals 
that the EGF polypeptide belongs to a part of a much larger precursor protein… 
"prepo-EGF" that is a transmembrane protein with molecular weight of 128kDa. So, 
6 
researchers have postulated that the mature EGF protein may be undergone cleavage 
by proteases from its precursor. (Gray et al, 1983). Recently, people found that the 
cleavage of prepo-EGF into mature EGF is regulated by a group of transmembrane 
metalloproteases (MMPs). (Izumi et al, 1998). But, the exact mechanism or method 
by which EGF is processed from its precursor molecule is not fiilly understood. {Rail 
et al, 1985). 
In fact, there is a family of EGF-like molecules (for example, transforming 
growth factor-a (TGF-a), amphiregulin (AR), heparin-binding EGF (HB-EGF), etc) 
existed and all of them are encoded by distinct genes respectively. (Carpenter and 
Wahl, 1990). (Table 2,1). The common features of these EGF-like growth factors are 
they all have high-affinity binding for the EGFR, possess ability to either stimulate or 
inhibit the growth of EGF-responsive cells and contain single or multiple EGF-like 
domains. (Salomon et al, 1995; Gullick, 2001). The characteristic of EGF-like 
domain is the presence of six conserved cysteine residues spaced at defined intervals 
within a region of approximately 50-60 amino acid residues in the general sequence 
within the EGF primary structure. {Carpenter and Wahl, 1990). The consensus 
organization for these cysteines is XnCX7CX2-3GXCXio-i3CXCX3YXGXRCX4LXn, 
where X refers to any amino acid. {Carpenter and Cohen, 1990). The cysteine 
residues can form three intra-molecular disulphide bonds that restrict the peptide 
7 
chain in a 3-loop secondary structure. {Figure 2.2). The presence of this arrangement 
of cysteines is very critical for its full biological activity and the binding to cognate 
EGF receptors. {Taylor et al, 1972). 
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On the other hand, based on nuclear magnetic resonance (NMR) studies of EGF， 
it was shown that EGF has two sets of anti-parallel (3-sheet structures with little or no 
a-helical conformation. {Mayo et al, 1989). 
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2.1.2 Epidermal Growth Factor Receptor (EGFR) 
As mention before, EGF specifically binds to EGFR in order to initiate a series 
of signal transduction that governing different biological processes. The epidermal 
growth factor (EGFR) is a well-studied and versatile signal transducer that has been 
conserved during evolution. 
2.1.2.1 The Structure of EGFR 
EGFR is a transmembrane receptor tyrosine kinase (RTK) that is responsible for 
a wide variety of physiological cellular processes. In fact, EGFR is a 170 kDa 
transmembrane glycoprotein that is composed of a single polypeptide chain of 1186 
amino acids. {Carpenter and Cohen, 1990; Wells, 1999). It contains three main 
regions, including an extracellular ligand binding domain, a transmembrane domain 
that contains a single hydrophobic anchor sequence and an intracellular domain that 
possess the intrinsic tyrosine kinase activity (receptor tyrosine kinase---RTK) {Ullrich 
et al, 1990) so that it is also known as the type I receptor tyrosine kinases or ErbB 
receptors. The schematic structure of EGFR was shown in Figure 23. It is because 
previous studies have pointed out the homology of EGFR and the v-erbE oncogenes 
so that it indicated that EGFR is also a cellular oncogene. {Downward et al, 1984; 
Lin et al, 1984; Xu et al, 1984). The characteristic of the possession of intrinsic 
10 
tyrosine kinase enzymatic activity of EGFR enables the signals to be transmitted 
across the plasma membrane where they activate gene expression and induce cellular 
responses ultimately. EGFR are widely expressed in all tissues where they regulate 
diverse functions. EGFR functions in regulation of a wide range of critical cellular 
processes including cell proliferation, differentiation and motility, etc. {Sibilia and 
Wagner, 1995). 
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Figure 2.3. The schematic structure of EGFR. EGFR contains the extracellular 
binding domain, the transmembrane domain and the cytoplasmic 
domain with intrinsic tyrosine kinase activity, 
(from Salomon and Gullick, 2001) 
2.1.2.2 The EGFR Family 
In mammals, EGFR is a part of a subfamily of four closely-related receptors that 
demonstrate homology in their kinase domains, but different in their extracellular 
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regions and C-terminal tails. Each member in the EGFR family share similar overall 
structure and amino acid sequence, but possess distinct properties. They are the EGFR 
itself (EGFR/HERl/ErbBl), HER-2/neu (ErbB2), HERS (ErbB3) and HER-4 (ErbB4). 
The EGFR family can be directly regulated by the binding of diverse ligands. Besides, 
it can also be activated by agonist that binds serpentine G protein-coupled receptors 
indirectly. {Prenzel et al, 2000). 
EGFR (ErbBl) is the first member to be studied and sequenced. (Ullrich et al.， 
1984). There are six ligands that can interact with EGFR are well characterized, 
including epidermal growth factor (EGF), transforming growth factor-a (TGF-a), 
amphiregulin (AR), heparin-binding EGF-like growth factor (HB-EGF), P-cellulin 
and epiregulin. In 1984, after the complete HERl cDNA was cloned from a 
HERl -overexrpressing cervical carcinoma cell line, its sequence can be elucidated 
that HERl was recognized as the human homolog of the avian oncogene v-erbB 
which is the tumorigenic element of the avian erythroblastosis vims. (Yamamoto et al, 
1983). Thus, erbB was the first example of how a normal gene can be converted into 
an oncogene. In addition, EGFR serves as a critical point of integration for multiple 
intracellular signal transduction pathways in cells. 
For HER2 (ErbB2), it is recognized as a human homologue of the rat neu 
oncogene. It shows considerable homology to the EGFR (Semba et al, 1985). 
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However, the function of this member is still poor understood. (Hackel et al, 1999). 
Furthermore, no direct ligand has yet been found to bind to HER2/neu receptor. But, it 
appears to play an important role in transmodulation of EGFR signaling as a result of 
heterodimerization with other members in the ErbB family. {Riese and Stern, 1998), 
For HER3 (ErbB3) and HER4 (ErbB4), they are two structurally related family 
members, but their functions are unclear. They can bind to heregulin and neuregulin. 
However, especially for HER3, it is different from other EGFR family members 
because it consists of deficient tyrosine kinase function. {Guy et al, 1994). In addition, 
for ErbB4 (HER4), similar to EGFR, it can also bind to EGF, P-cellulin and epiregulin. 
(Komurasaki et al, 1997). These receptors can trigger multiple downstream signaling 
pathways within a rich multi-layered network and give various combinational 
responses. 
2.1.2.3 EGFR Activation 
Firstly, EGFR exist as an inactive monomer in the cell membrane. After ligand 
binding to EGFR, it can induce homodimerization or heterodimerization between 
EGFR and other receptor members of the ErbB family. After that, the intracellular 
tyrosine kinase domain of EGFR becomes activated so that the tyrosine residues on 
EGFR receptor would undergo autophosphorylation and it then leads to 
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cross-phosphorylation to the other member of the receptor pair. {Schlessinger, 2000) 
(van der Geer and Hunger, 1994). The docking sites created on the receptor will 
recruit SH2 and PTB domain containing proteins that will associate with the activated 
receptor to generate an active signaling complex. {Pawson and Nash, 2000). After that, 
these signaling complexes are dissociated so that those activated effectors and adapter 
proteins are released into the cytoplasm. Following this interaction, subsequent 
tyrosine phosphorylation and activation of various proteins are generated so that a 
cascade of signaling transduction pathways can be triggered that can culminate in 
gene transcription and cause changes in the phenotypes of the cell ultimately. {Hill 
and Treisman, 1995). The simplified flow diagram and pictorial description of EGFR 
activation were shown in Figure 2.4 and Figure 2.5 respectively. 
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Ligand binding to the extracellular 
binding domain of EGFR 
> f 
Receptor oligomerization 
(Homodimers or heterodimers were formed between 
EGFR and other EGFR family members) 
> ( 
Induce auto- and cross- phosphorylation of 
tyrosine residues of EGFR 
> f 
EGFR becomes activated and create 
binding sites for recruitment of various 
tyrosine kinase substrates 
> f 
Initiate a series of multiple divergent signal 
transduction pathways and cause alteration of 
specific genes expression 
Figure 2.4. The simplified flow diagram about the steps of EGFR activation after 
ligand binding. 
(from Wells and Sedlacek，2000) 
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Figure 2.5. How EGFR becomes activated. After the EGF binding to EGFR, it can 
induce dimerization of receptor and then autophosphorylation between 
receptors is triggered and EGFR becomes activated, 
(from Cell biology, Chapter 10, pp.282) 
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On the other hand, for EGFR signaling termination, receptor endocytosis and 
degradation of the receptor-ligand complex are critical mechanisms that are generated 
by the activated EGFR. (Sorkin and Waters, 1993; Waterman and Yarden，2001). The 
contents of the resulting endosomes are then either undergone degradation or recycled 
to the cell surface. {Wells, 1999). {Figure 2.6) 
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Figure 2.6. The proposed model of the EGFR signal transduction. After ligand binding 
to EGFR, receptor dimerization and cross-phosphorylation were induced. A 
transient signaling complex that included effector and adaptor proteins was 
generated. Then, a cascade of signal transduction lead to gene activation and 
different cellular responses were triggered due to the dissociation of the 
signaling complex. During EGFR signal termination, the ligand-receptor 
complex were internalized and then either degraded or recycled to the cell 
surface. “P” refers to phosphorylated. 
(from Yarden and Kelman, 1991) 
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2.1.3 The Intracellular Signal Transduction Pathways in EGFR 
Signaling 
As mention previously, after ligand-binding, receptor autophosphorylation is 
induced. It can recruit and further phosphorylate a series of several intracellular 
substrates as well as binding of differential docking and adaptor molecules to specific 
phosphotyrosine sites on EGFR. As a result, a variety of signal transduction cascaded 
will be simulated. So, EGFR is one of the critical point of crosstalk for the cell to 
integrate information from a series of distinct signaling pathways. In fact, there are 
three major downstream signaling pathways in EGFR signaling. {Figure 2.7). 
EGFR I ' - - jp=JL , Tyrosine 
.:,Phosphorylated O O \ ^ ^ 
/ 一— n i^rn I T^f I 
/ I PI3 kinaseH \ ^ . . J L ^ 
/ ‘ ； ‘ ^ C M E Q 
I __7\ 
PTEN 1 ( A k t � \ 
夕 ^^^ Activation of gene > 
I � P r o耐a t i o n | | | I Differentiation | 
Figure 2.7. The three major downstream intracellular signal transduction pathways 
involved in EGFR signaling. They axe the Ras/Raf/MAPK pathway (shown 
in orange color); the Jak/Stat pathway (shown in blue color) and the 
PI3K/Akt pathway (shown in yellow color), 
(modified from Johann S de Bono et al, 2002) 
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2.1.3.1 The Ras/Raf/MAPK Pathway (MAPK pathway) 
The first major EGFR downstream signaling pathways is the Ras-Raf-MAPK 
pathway (MAPK pathway). {Alroy and Yarden, 1997). Ras is a small 
membrane-bound guanine nucleotide-binding protein with intrinsic GTPase activity 
that serves as an important molecular switch to transmit signals from activated 
receptors to downstream effectors in order to mediate cell proliferation, cell survival 
and differentiation. Also, a lot of evidences have pointed out that Ras is a pivotal 
signaling molecule in RTK-mediated proliferation. (Pronk and Bos, 1994). Besides, 
Ras cycles between an inactive GDP-boimd state and an activated GTP-bound state. 
{Bourne et al, 1991). {Figure 2.8). Ras can be activated by guanine nucleotide 
exchange factor (GNEF) by converting Ras-GDP into Ras-GTR Oppositely, Ras can 
be inactivated by GTPase-activating proteins (GAPs) by promoting the conversion of 
Ras-GTP into Ras-GDP. 
tv ( ^ s -GPP^ ^^ ^^ ^ Figure 2.8. The Ras cycle. Ras cycle between 
Pi QP the inactive GDP-bound Ras and 
) C GNEF the active GTP-bound Ras. The 
cycle is regulated by GNEF that 
M V T l ( ^ Z GDP can activate Ras and GAP that can 
->Ras-GTP^ down-regulate Ras. 
(modified from Signal 
^ transduction in cancer, pp. 191) 
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Once in the active GTP-boimd state, activated Ras can interact with several 
effector proteins in order to stimulate numerous intracellular processes by engagement 
of a series of cascade of phosphorylation. Raf-1 is one of the effector proteins of Ras 
and the Raf-MEK-ERK pathway represents one of the best characterized Ras 
signaling pathways. (Figure First of all, Ras activates and interacts with Raf-1 in 
a GTP-dependent manner. (Daum et al, 1994; Stokoe et al, 1994). Raf is a 
serine/threonine protein kinase. A family of Raf proteins kinases has been identified 
and it includes A-Raf, B-Raf and C-Raf. In addition, it has been suggested that this 
family of kinases is responsible for regulation of cell proliferation, differentiation and 
apoptosis. {Hagemann and Rapp, 1999). 
After Raf becomes activated, it phosphorylates and activates the 
MAP-kinase-kinase (MAPKK or MEK) that is the dual specificity kinase by 
phosphorylating on its two distinct serine residues. {Crews et al, 1992; Dent et al, 
1992; Her et al, 1993). After that, the activated MEK then phosphorylates and 
activates MAPK, including ERKl and ERK2 on both tyrosine and threonine residues. 
{Anderson et al, 1990")�There is evidence to indicate that currently there are no other 
identified substrates for MEK except ERKl and ERK2. (Seger et al” 1992). The 
significance of this tight selectivity as well as the unique ability to phosphorylate both 
tyrosine and threonine residues are consistent with the central role of this kinase in 
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integration of cellular signals into the MAPK pathway. Then, activated MAPK 
phosphorylates a variety of cytoplasmic and membrane proteins. In addition, MAPK 
can also be translocated into the nucleus where it phosphorylates and activate a series 
of transcription factors. {Karin and Hunter, 1995; Hunter, 2000). Therefore, it can 
trigger a cascade of cellular responses, including cell proliferation, survival and 
transformation. {Lewis et al, 1998). 
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Figure 2.9. The Schematic representation of the Ras/Raf/MAPK pathway. 
The MAPK cascade contains three sequential kinase: MAP kinase 
kinase kinase (Raf); MAP kinase kinase (MEK, and MAP kinase 
(ERK). 
(from Judith S Sebolt-Leopold, 2000) 
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In fact, the MAPK activity is regulated through a three-tiered kinase cascade that 
is composed of a MAPKK kinase or MEK kinase (MAPKKK or MEKK), a MAPK 
kinase (MAPKK，MKK or MEK) and a MAPK. {Figure 2.10). There are a lot of 
members in each family of kinases in this MAPK module. Apart from these, this 
signaling cassette is highly conserved in the evolution and it plays a critical role in the 
control of metabolic processes, such as cell cycle, cell migration, cell shape as well as 
cell proliferation and differentiation. (Davis, 2000). In mammals, it contains at least 
four distinctly regulated groups of MAPKs (for example, extracellular signal-related 
kinase—ERKl/2, Jim amino-terminal kinases —JNKl/2/3, p38, etc) that are activated 
by specific MAPKKs (such as, MEKl/2 for ERKl/2 respectively). However, a 
MAPKK can be activated by at least more than one MAPKKK, therefore, it can 
greatly increase the diversity and complexity of the MAPK signaling pathway. 
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Figure 2.10. The MAPK pathway. This highly conserved signaling cassette contains a 
MKKK, a MKK and a MAPK. For MKKK, it can respond to a variety of 
extracellular stimuli, including growth factors, differentiation factors and 
stress. Then, the activated MKKK can then activate one to several MKKs. 
For MKK, it is relatively specific for their particular target MAPK. Once 
activated, MAPK can phosphorylate a set of transcription factos and trigger 
multiple cellular responses, 
(from Timothy and Gary, 1999) 
2.1.3.2 The Jak/Stat Pathway 
Comparatively, the Jak/Stat pathway is a newly discovered intracellular signal 
transduction pathway that is participated in a variety of extracellular signaling 
proteins (ESPs) (for example, growth hormones, growth factors—EGF, 
cytokinesinterferons and interleukins, etc) in order to activate the transcription of 
specific sets of target genes. At first, the Jak/Stat pathway was identified as serving a 
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key role in hematological and interferon signaling. Until now, evidence has shown 
that many additional ESPs also can activate the Jak/Stat pathway as well. (Shuai et al, 
1993). In the Jak/Stat pathway, it consists of a chain of specific protein-protein 
interaction that leads to a specific protein-DNA interaction in the nucleus finally. 
Jaks (Janus kinases) are cytoplasmic non-transmembrane tyrosine kinases and 
there are four members in the Jak family in mammals, including Jakl, Jak2, Jak3 and 
Tyk2. (Ihle, 2001). They range in size from 120-130kDa and express ubiquitously in 
many tissues, except Jak3. {Leonar and O 'Shea, 1998). It is because the expression 
of Jak3 seems to be limited in cells of myelocytic and lymphocytic linkage. 
(Kawamum et al, 1994). Unlike the other soluble tyrosine kinases, Jaks lack a SH2 
{src homology 2) or SH3 {src homology 3) domains that can act as a modular protein 
domain to mediate specific protein-protein interactions. (Pawson, 1995). One of the 
unique characteristic of Jaks is the presence of two tandem tyrosine kinase domains, 
that is contributed to the origin of its name. In addition, it contains seven conserved 
Jak homology (JH) domains from JHl to JH7. {Muller et al, 1993). According to the 
Jak structure (Figure 2.11), it includes a distinctive pseudokinase domain (JHl) and a 
tyrosine kinase domain (JH2) at the carboxyl-terminal portion. {Ihle, 2001). 
Evidences show that JH2 is essential for JHl catalytic activity. {Yeh et al, 2000) and 
the remaining domains (JH3-JH7) are believed to be implicated in receptor 
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association. {Kisseleva et al, 2002). 
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Figure 2.11. The structure of Jaks. 
(modified from Christian W. Schindler，2002) 
For Stats (Signal Tansducers and Activators of Transcription), there are seven 
Stat proteins identified in mammals, including Statl-Stat 7 that range in size from 750 
and 850 amino acids. Stat proteins are latent transcription factors. It can bind to 
specific sequence elements in the promoters of genes in the nucleus and then enhance 
the activation of the transcription of these specific sets of genes. Under basal 
physiological condition, Stats are predominantly localized in the cytoplasm. However, 
in the presence of ligand binding, the receptor-associated Jak kinases phosphorylate 
Stats on a single tyrosine residue located on the carboxyl terminal of the SH2 domain. 
{Shuai et al, 1993). After that, two Stats dimerize through specific reciprocal 
SH2-phosphotyrosine interaction. Then, the Stat dimmers translocate to the nucleus 
and bind to the specific DNA response elements in the promoters of the target genes. 
Therefore, Stats have dual role in the Jak/Stat signaling so that they were named 
signal transducers and activators of transcription. Based on the structure of Stats 
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(Figure 2.12), it can be divided into several structurally and functionally conserved 
domains. {Becker, 1998). It consists of the amino-terminal domain (NHi), the 
coiled-coil domain (CCD), the DNA-binding domain (DBD), the linker domain and 
the SH2/tyrosine activation domain. The amino-terminal domain is responsible for 
promoting cooperativity in DNA binding and regulation of nuclear translocation. 
(Vinkemeier et al, 1998). The coiled-coil domain (CCD) can be associated with a 
number of critical regulatory modifiers. {Horvath, 2000). The DNA-binding domain 
(DBD) can recognize members in GAS family of enhancers and modulate the nuclear 
export. {McBride, 2000). The linker domain is used for ensuring that correct structure 
of the DNA-binding motif and regulate nuclear export in resting cells. The SH2 
domain is the most highly conserved motif and it can mediate receptor-specific 
recruitment and Stat dimerization. (Kisseleva, 2002). Finally, at the carboxyl-terminal, 
the transcriptional activation domain (TAD) contributes to Stat specificity. 
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Figure 2.12. The structure of Stats. 
(modified from Christian W. Schindler, 2002) 
For the signaling in the Jak/Stat pathway, first of all, after the binding of 
extracellular signaling proteins (ESPs), such as growth factors, hormones, cytokines, 
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etc., it can initiate the aggregation of two or more transmembrane receptor chains. 
After that, the induced conformational changes can bring receptor-associated Jaks into 
apposition. Then, the Jaks phosphorylate and activate each other sequentially by 
phosphorylating the receptor tyrosine residues. This can initiate the recruitment of 
specific Stats and bind to the receptor phosphotyrosine residues and become activated 
on a tyrosine residue. In some cases, except tyrosine residue, Stats can also be 
activated on a serine residue as well, possibly through the MAP kinase. Evidence also 
showed that the serine phosphorylated Stats are shown to have stronger transcriptional 
activation activity. (Wen et al, 1995). Then, the activated Stats are released from 
receptors and dimerize and then translocate in to the nucleus. After that, the complex 
can bind to the specific response elements of target gene and enhance its transcription 
rate greatly. (Figure 2.13). 
In the highly complicated Jak/Stat pathway, different ligands can evoke different 
members of the Jaks and Stat families specifically. Also, due to the specific binding of 
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2.1.3.3 The PI3K/Akt Pathway 
Although the Ras/Raf/MAPK pathway and the Jak/Stat pathway are the two 
major signaling pathways involved in EGFR signaling. However, in response to EGF, 
the PBK/Akt signaling pathway can also be activated and it plays a crucial role in 
effecting alterations in a broad range of cellular functions, too. And this pathway is 
highly conserved among different species. {Brogiolo et al, 2001). (Figure 2.14). 
Phosphoinositides (Ptdlns) are rare lipids. Once activated and localized to the 
plasma membrane, PI3K (phosphoinositol 3-kinase) phosphorylates these 
phosphoinositol lipids on the 3'-hydroxyl group of the inositol ring to generate 
PtdIns-3-phosphates (PtdIns-4,5-P2 and PtdIns-3,4，5-P3) that are important second 
messengers in cell signaling pathways. Then, these specialized phosphorylated lipids 
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can specifically recruit many signaling proteins that containing pleckstrin homology 
(PH) domain, including serine-threonine kinases (Akt), protein tyrosine kinases and 
exchange factors that regulate G-proteins, etc to the membrane. Originally, these 
proteins are present in the cytosol in an inactive form, however, when localized to the 
membrane, they become activated and involved in assembly of signaling complexes 
and then initiate a series of kinases casades. 
Akt is a 57kDa serine-threonine protein kinase that is also known as protein 
kinase B (PKB). It serves as a critical mediator in multiple downstream signaling in 
the PI3K pathway. But, activation of Akt is a multi-steps process involves both 
membrane binding and phosphorylation. As mention before, after PI3K activation and 
PIP2 and PIP3 generation, Akt is recruited to the membrane by binding to these 
phosphoinositides through its PH domain. (Franke et al, 1997). After that, Akt can 
phosphorylate multiple downstream substrates (such as, GSK3, BAD, caspase 9, 
NF-kB, etc) (Altiok et al, 1999; Zhou et al, 2001) on their serine and threonine 
residues and regulate a variety of critical cellular functions, including cell 
proliferation, cell survival, glucose metabolism, etc. Phosphorylation of BAD can 
prevent apoptotic cell death by blocking its complex formation with the apoptotic 
protein Bcl-2 and Bcl-xl. (Datta et al, 1998). PKB-induced phosphorylation of the 
transcription factor --- FKHRl suppresses proapoptotic gene expression so that it can 
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inhibit the progress of apoptosis. {Brunet et al, 1999). Insulin-induced activation of 
PDKl can lead to phosphorylation and activation of S-6 kinase. In addition, glycogen 
synthase kinase-3 (GSK-3) and phosphofruckokinase that are regulated in response to 
insulin stimulation are phosphorylated by Akt also. (Toker and Newton, 2000). 
On the other hand, PTEN (phosphatase and tensin homolog deleted on 
chromosome 10) is a tumor suppressor. It is both a protein and a lipid phosphatase. 
{Cantley & Neel, 1999; Vazquez & Sellers, 2000; Maehama et al, 2001). Therefore, 
PTEN can dephosphorylate the D3 position of PtdIn-3,4-P2 and PtdIns-3,4,5-P3 that 
are generated by PI3K. (Maehama & Dixon, 1998). As a result, PTEN can antagonize 
the downstream signaling in PI3K pathway� 
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Figure 2.14. The PI3K/Akt pathway. 
(modified from Signal transduction in cancer, pp. 146) 
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2.1.4 EGFR and Cancer 
Normally, EGFR is expressed in all epithelial cells and a lot of mesenchymal 
cells. The receptor also serves multiple important roles during normal development, 
from controlling cell growth and differentiation to organ repair in adults. {Wells, 1999). 
However, alteration and dysregulation of EGFR itself or its signaling transduction 
have been implicated in many aspects on tumor biology and pathogenesis of many 
human cancers. {Wells, 2000). (Figure 2,15). 
First of all, elevated level of EGFR is observed in a wide variety of human 
tumors, including prostate, breast, gastric, colorectal and ovarian. {Salomon et al, 
1995). Over-expression of EGFR in tumors has been proved to be directly correlated 
with disease progression, poor survival, poor response to therapy {Brahender et al, 
2001) and the development of resistance to cytotoxic agents. {Meyers et al, 1988; 
Wosikowski et al, 1997). The mechanisms of EGFR over-expression are mainly 
contributed by transcriptional activation and gene amplification. {Grandis et al, 1996; 
Rubin and Grandis, et al, 1996; Nagatsuka et al, 2001). Because of the increased 
expression of EGFR, the EGFR signaling pathways become hyper-activated, as a 
result, uncontrolled cell growth occurred and that contributes to cancer formation 
finally. In addition to over-expression of EGFR, co-expression of EGFR and its 
ligands (eg: EGF, TGF-a) can also result in activation of an autocrine system that 
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leads to dysregulated EGFR action and uncontrolled cell growth. {Salomon et al, 
1995). (Table 2.2) 
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Apart from these, the EGFR signaling can also be up-regulated via alternative 
mechanisms. EGFR can heterodimerize with HER2 and cross-talk with heterologous 
receptors, such as G-protein-coupled receptors (GPCRs) so that it can potentiate 
EGFR signaling activation by increasing ligands binding affinity, stabilizing and 
recycling the receptor heterodimers and expanding the repertoire of 
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receptor-associated substrates and its signal responses. (Karunagaran et al, 1996; 
Worthylake et al” 1999). 
On the other hand, EGFR mutation is one of the main reasons for 
carcinogenesis. There are two common mutated forms of EGFR, including secreted 
EGFR (sEGFR) and EGFRv. They are generated by alternative spicing and deletions 
in the extracellular ligand-binding domain respectively. For EGFRv, EGFRvIII 
mutant is the most common forms involved in human cancers. (Moscatello et al” 
1995; Wikstrand et al, 1995). It is a 145kDa truncated EGFR mutant that lacks an 
external ligand-binding domain and expressed exclusively in cancer cells. Hence, it 
cannot bind to any ligands. However, it has a constitutively activated, but attenuated 
tyrosine kinase activity which can stimulate EGFR signaling independently of ligand 
interaction. {Nishikawa, 1994). Besides, EGFRvIII is commonly expressed as a result 
of gene amplification and has been identified in brain, lung, breast, prostate and 
stomach cancers. (Raymond et al, 2000). 
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Figure 2.15. The close relationship between EGFR signaling and the 
pathogenesis of cancers. Here is the summary of the multiple 
mechanisms contributed to elevated activation of the EGFR signal 
transduction. "R" refers to receptor; "S" refers to substrate; ‘‘K,, 
refers to kinase; “pY” refers to phosphotyrosine. 
(from Carlos, 2002) 
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2.1.5 EGFR-targeted Cancer Therapy 
EGFR-targeted therapy is a novel option for cancer treatment. In fact, several 
aspects of EGFR-targeted therapies have been developed and examined in clinical 
trials already. And the outcome of these results is very encouraging. However, due to 
the complication of the EGFR signaling networks, the details about exploiting novel 
targeting agents is still in its infancy. But, one point can be ensured that is 
understanding more about the details of the EGFR signaling system can really help 
people to promote new agents and optimize the cancer therapy currently available. 
Briefly, the currently available EGFR-targeted therapies fall into few types. (Figure 
2.16). 
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Figure 2.16. The summery about several strategies of currently developed and 
novel EGFR-targeted therapies for cancer treatment. 
(from Noonberg and Benz, 2000) 
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2.1.5.1 Monoclonal Antibody (MAb) 
MAbs are generally directed at the extracellular domain of EGFR in order to 
block ligand binding and the subsequent EGFR signaling activation. One promising 
and currently used in clinical trials MAb is IMC-C225. It is a chimeric human-mouse 
MAb that contains the human IgGl constant region and it has recently been 
developed and purified for clinical purpose. {Goldstein et al, 1995; Mendelsohn, 
2000). Moreover, studies also showed that the effect can be enhanced when 
IMC-C225 is combined with common anticancer drugs (such as, doxorubicin, 
cisplatin, etc). (Figure 2.17). For instance, it can inhibit EGF-induced receptor 
activation in prostate carcinoma cell lines (DU145 and PC-3) alone or in combination 
with doxorubicin. (Prewett et al, 1996). Several in vitro experiments and in vivo 
animal studies have also shown an enhancement in the radiation sensitivity in tumors 
by IMC-C225 in human epidermoid, head and neck, and colon cancer xenograft. 
{Milas et al, 2000). 
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2.1.5.2 Immunotoxin Conjugates 
MAb can be conjugated with potent cellular toxin (for example, Pseudomonas 
aeruginosa toxin). Thus, after the binding of EGFR, the receptor complex will be 
prompted to undergo internalization and being translocated to the cytosol. And the 
toxin can then block the subsequent protein synthesis and induce cell death in tumor 
cells finally. (Azemar et al, 2000). Until now, several immunotoxin conjugates are 
performed in preclinical trials. (Schmidt et al” 1999). Moreover, a recent approach in 
development of EGFR-targeted cancer therapy is the use of recombinant proteins, 
containing EGF or TGF-a, to fuse with toxin or tyrosine kinase inhibitors in order to 
interfere the EGFR signaling and prevent uncontrolled cell growth in tumor cells. And 
the outcome of these clinical trials is encouraging. 
2.1.5.3 Bispedfic Antibody 
These kinds of antibodies contain dual specificity since they have two different 
antigen binding sites. One site is specific for the extracellular domain of EGFR; 
another site is engineered for the binding to the epitopes on the surface of immune 
effector cells. As a result, it can prevent EGFR signaling and enhance the recruitment 
of the immune effector cells at the site of tumor so that it can initiate the destruction 
of tumor cells and then stimulate additional immune responses. {Negri et al, 1995). 
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For example, CD64 is a bispecific antibody that specific for EGFR and the IgG 
receptor and it is being used in the early clinical trials. {Goldstein et al, 1997). 
2.1.5.4 Small-molecule EGFR Tyrosine Kinase Inhibitors (EGFR-TKIs) 
Another approach of the EGFR-targeted therapy is to target the intracellular 
tyrosine kinase domain of EGFR by employing small-molecule EGFR tyrosine kinase 
inhibitors. These inhibitors can inhibit the ATP binding to the tyrosine kinase domain 
of EGFR, thereby preventing its tyrosine kinase activity and subsequent 
autophosphorylation so that the EGFR signal transduction can be blocked. Also, 
EGFR-TKI is the most promising class of compound that can give encouraging 
clinical outcome among those EGFR-targeted therapies. {Figure 2,18). 
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One of the well-known TKI is ZD 1938 (Iressa™). It is a low molecular weight 
synthetic anilinoquinazoline. It can inhibit autophosphorylation of EGFR isolated 
from A431 vulval carcinoma cells, with an IC50 of 0.023-0.079uM. (Woodburn and 
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Barker, 1996). Furthermore, cytostatic growth inhibiting activity of ZD 1839 has also 
been demonstrated in a wide range of human cancer cell lines that express functional 
EGFRs, including prostate, breast, ovarian, colon Qtc.(Ciardiello et al” 2000; Sirotank 
et al, 2000). Apart from these, enhancement of cell growth inhibition, induction of 
apoptosis and increased antitumor activity in vivo and in vitro were investigated when 
ZD 1839 combined with common anti-cancer drugs, such as cisplatin, paclitaxel, 
doxorubicin, etc. (Ohmori et al, 2000). In addition, studies also showed that ZD 1839 
can have an additive and synergistic effect when combined with ionizing radiation in 
several NSCL cancer cell lines in vitro. (Raben et al, 2000) 
2.1.5.5 Antisense Oligonucleotides 
Antisense oligonucleotides are short pieces of synthetic, chemically modified 
DNA or RNA that can specifically bind to their complementary mRNA and then 
inhibit the corresponding protein expression. {Wagner, 1994). {Figure 2.19). Due to 
its highly selective targeting in a sequence-specific manner, recent studies indicated 
that antisense oligonucleotides specific for the EGFR ligands and EGFR can give 
good results in vitro and in animal models. Moreover, it is begun to be used in early 
clinical trials now. {Witters et al, 1999; Casamassimi et al, 2000). 
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Figure 2.19. The pictorial description of the theory of antisense oligonucleotide action, 
(from http://www. cem. msu. edu/�cem 181 h/poj ects/97/antisense/anti. htm) 
To conclude, traditional chemotherapy and radiotherapy can let cancer patients 
suffer from lots of awful side-effects. But, now, EGFR-targeted therapies can give a 
new hope to cancer patients. According to many research studies, it can also suggest 
that the combination therapy by using the common anti-cancer drugs or agents with 
the EGFR-targeted strategies can really enhance the effectiveness of the regression of 
tumor cells. In addition, clinical trials also showed that these therapies are generally 
more well-tolerant and have milder side-effects instead. However, the details about 
the effect of blocking EGFR signaling as a whole and the long-term influences of 
these therapies have not fully understood. So, subsequent studies should be needed in 




Recently, targeting EGFR and its downstream signal transduction pathways is a 
new promising direction in cancer therapy because these kinds of EGFR-targeted 
therapies are relatively less toxic and more tolerable for cancer patients than those 
traditional cancer treatments, such as high-dose chemotherapy. However, the EGFR 
signaling network is absolutely complicated and many aspects are still not fully 
understood. In particular, how targeting EGFR signaling may alter the behavior of 
cells in response to growth factor itself and also to other chemotherapeutic drugs is 
still not clear. Such kind of knowledge of EGFR signaling will be important as to 
develop a more effective way of targeting the signal pathway in cancer therapy. 
In the present study, EGF-conditioned cells were established by chronic exposure 
of human squamous carcinoma A431 cells to EGR The responses of A431 parent cells 
and EGF-conditioned cells to EGF were first compared by MTT assay. It is believed 
that the differential growth responses to EGF in two cell lines may be somehow 
correlated with the alteration of EGFR signaling caused by EGF-conditioning. 
Therefore, the expression levels of different signaling molecules involved in EGFR 
signaling were determined by Western Blot analysis for studying in this aspect. After 
that, the responses of various EGFR signaling modifiers in combination with EGF 
between A431 parent cells and EGF-conditioned cells were also studied. 
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2.3 Materials and Methods 
2.3.1 Materials 
Chemicals Company 
> 2-mercaptoethanol Sigma 
> 2X trypsin with EDTA Gibco / Life Technologies, Ltd. 
> 3-[4,5-Dimethtlthiazol-2-yl]-2,5-diphenyl-tetrazolium 
bromide (MTT) S — a 
> Acrylamide / Biacrylamide BIO-RAD 
> AG490 Calbiochem 
> Ammonium persulphate Sigma 
> Apigenin Calbiochem 
> Aprotinin Boehringer Mannheim 
> BCA protein assay reagent Boehringer Mannheim 
> Benchmark prestained protein marker Invitrogen Corporation 
> Bromophenol blue Sigma 
> Butanol BDH Laboratory Supplies 
> Copper (II) sulphate* 5H2O Sigma 
> Diethyl pyrocarbonate (DEPC) USB 
> Dimethyl sulfoxide (DMSO) Sigma 
> Dulbecco's modified eagles's medium (DMEM) Gibco / Life Technologies, Ltd. 
> ECL Western blotting detection reagents Amersham Biosciences 
> EGF Prepotect 
> Ethanol BDH Laboratory Suppliers 
> Fetal bovine serum (FBS) Gibco / Life Technologies, Ltd. 
> Glycerol Sigma 
> Glycine Invitrogen Corporation 
> Jak inhibitor 1 Calbiochem 
> L744832 Calbiochem 
> Leupectin Boehringer Mannheim 
> L-glutamine Gibco / Life Technologies, Ltd. 
> LY294002 Calbiochem 
> Magnesium chloride Sigma 
> Methanol BDH Laboratory Suppliers 
> N,N,N,,N,-tetramethylethylenediamine (TEMED) BIO-RAD 
> PD98059 Calbiochem 
> Penicillin-streptomycin (PS) Gibco / Life Technologies, Ltd. 
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> Phenylmethysulfonylfluorid (PMSF) Boehringer Mannheim 
> Phosphate buffer saline (PBS) Gibco / Life Technologies, Ltd. 
> Polyoxyethylenesorbitan monolaurate (Tween 20) USB 
> SB203580 Calbiochem 
> Sodium dodecyl sulfate (SDS) Gibco / Life Technologies, Ltd. 
> Sodium ortho-vanadate Sigma 
> Thimersol Sigma 
> Tris-base USB 
> Triton X-100 Boehringer Mannheim 
> Tryphostin A25 Calbiochem 
> ZM336372 Calbiochem 
Culture Wares Company 
> 60 mm and 100 mm culture dishes Coming / Falcon / IWAKI 
> 75 cm2 culture flask Coming / Falcon / IWAKI 
> 96-well flat-bottom culture plate Coming / Falcon 
> Microfuge tubes MBP 
Instruments Company 
> Film cassette Kodak 
> Immobilon-P transfer membrane Millipore 
> Microplate Reader Molecular Device 
> Mini-PROTEAN® II Electrophoresis Apparatus BIO-RAD 
> Thick blotter papers BIO-RAD 
> Trans-Blot® SD Semi-transfer cell BIO-RAD 
> X-rays film Kodak / Fuji 
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2.3.2 Methods 
2.3.2.1 Cell Lines 
Two sublines of human squamous carcinoma A431 cells were employed. One 
was the human squamous carcinoma A431 parent cells (AP cells) and another one was 
EGF-conditioned A431 cells (AC cells). Both of them were cultured in Dulbecco 
Modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) 
and 5mM L-glutamine in the humidified 37^C incubator supplied by 10% CO2. 
2.3.2,1,1 Establishment of Epidermal Growth Factor (EGF)- conditioned A431 
Cells (EGF-conditioned Cells)—AC Cells 
The human squamous carcinoma A431 parent cells were first cultured with 
50ng/ml epidermal growth factor (EGF) continuously for 30 weeks. After that, those 
cells were considered as the EGF-conditioned A431 cells. For cell culture stocks, 
50ng/ml EGF would be included in the medium for each passage. On the other hand, 
to prepare the EGF-conditioned A431 cells for experiment, the cells were first 
cultured in medium without EGF for at least further 4 to 5 days in order to eliminate 
the residual cytokines effects. After this EGF-free period, the cells were ready for 
different experiments. To target the EGFR signaling pathway, antibodies and specific 
inhibitors but not EGF itself are currently developed and used in clinic for cancer 
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treatment. {Section 2.1.5). However, all these agents are known to act on and may 
then alter the signaling pathway. Therefore, the EGF-conditioned cells may serve as a 
model to examine how alteration of signaling pathways may affect the therapeutic 
response pattern of cancer cells. 
2.3.2.2 Growth Curve between A431 Parent Cells and EGF-conditioned Cells 
Firstly, 1x10^ A431 parent cells and EGF-conditioned cells were seeded in 60 
mm culture dishes and grown in 10% serum DMEM medium. Then, cells were 
trypsinized and collected. After that, cells were spinned down at 1000 rpm for 5 
minutes. Cells were resuspended in 10% serum DMEM medium again and the cell 
number of A431 parent cells and EGF-conditioned cells were counted by 
hemacytometer. The cell numbers in two cell lines were counted at the same time 
everyday for a week. Then, the growth curve was plotted on a semi-log scale for 
observation. Each time point represented the average of two independent experiments. 
2.3.2.3 Epidermal Growth Factor (EGF) Sensitivity Assay 
In order to determine the effects of epidermal growth factor (EGF) on the growth 
of the A431 parent cells and the EGF-conditioned cells, MTT assay was employed. 
Briefly, 6x l0^/100jLi l A431 parent cells and 12x10^/1 00|LI1 EGF-conditioned cells were 
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seeded in the 96-well flat bottom plates for 2 days and the cells were at exponential 
phase. Then, different concentrations of EGF were added. In the experiments that 
examining the influence of EGF signaling modifiers on EGF growth effect, the 
signaling modifiers were added to the cells at the same time as that of EGF. After 
further 5 days incubation, medium in 96-well plates were removed by suction syringe 
and 50|al of Img/ml MTT solution in IX PBS was added in each well. The cells were 
then incubated at 37^C for 3-4 hours and the yellow-coloured tetrazolium ---
3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyl tetrazolium bromide (MTT solution) will 
be converted into a purple formazan that is catalyzed by the mitochondrial 
dehydrogenase of the viable cells. After incubation at 37^C, 150^1 dimethyl 
sulphoxide (DMSO) were added to stop the reaction and to dissolve the purple 
formazan for afterward measurement. Then, the plates were stayed at room 
temperature for 30 minutes and shaken for 10 minutes by shaker. Next, the 
absorbance could be read at 570mn by the microplate reader. The sensitivity to EGF 
of the two cell lines was then calculated and plotted by the following formula: 
=ODave of sample - OD of blank x 100% 
ODave of control — OD of blank 
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2.3.2.4 Western Blot Analysis 
In order to determine the differential protein expression pattern of various 
signaling molecules involved in the EGFR signal transduction pathways in both A431 
parent cells and EGF-conditioned cells, Western Blot analysis were employed. 
2.3,2,4,1 Protein Samples Preparation 
First of all, cells were seeded in 60 mm culture dishes until it reached 80% 
confluence (4x10^ for A431 parent cells and 5x10^ for the EGF-conditioned cells). 
Then, medium was removed and washed with ice-colded IXPBS and ortho-vanadate. 
Cells were lysed in 50|LI1 Lammaeli's buffer (including 2.1|ig/ml aprotinin, 1 jiig/ml 
leupeptin, 4.9mM MgCli, lOOmM sodium ortho-vanadate, 10% Triton X-100 and 
lOOmM PMSF in IX PBS). After that, cells were scraped by cell lifter and the cell 
lysate were collected in a 1.5ml microfuge tube. The cell lysates were then 
centrifuged at maximum speed (14000 rpm) at for 7 minutes. Next, 0.5|LI1 of the 
supernatant of the cell lysate was added into a 96-well plate in triplicate for 
subsequent quantification of protein concentration by protein assay. In addition, the 
volume of supernatant of each sample was measured and collected into a new 1.5ml 
microfuge tube. After that, equal volume of 2X sample buffer (including 0.125M Tris 
base, 20% w/v glycerol, 10% 2-mercaptoethanol, 4.6% SDS and bromophenol blue, 
pH 6.8) was added into each sample. Finally, protein samples were denatured by 
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boiling at lOO^C for 10 minutes. Then, those samples were kept at -20^C for further 
experiment. 
2.3.2.4,2 Protein Assay (by BCA Protein Assay Reagent) 
0.5|al of the supernatant from the cell lysate of each protein sample were used 
for subsequent protein assay in order to determine the protein concentration in each 
sample. At the time of the measurement, a standard curve for protein concentration 
was also generated. A series of different concentration of protein stock solution, 
including 0.5|Lig/ml protein stock solution and 2\iglm\ protein stock solution, were 
used for this purpose. Then, working BCA Protein Assay Reagent was prepared by 
combining Reagent A and Reagent B in the ratio of 50:1 (i.e. 9.8ml Reagent A + 
0.2ml Reagent B— <Copper(II) sulphate�). 0.2ml working BCA Protein Assay 
Reagent was added in to each well of the 96-well plates. The plate was allowed to 
incubate at 37^C for 30 minutes. The absorbance for each well of the plate was then 
measured at wavelength 540 nm by microplate reader. After that, the concentration of 
each protein sample could be determined by calculation from the protein standard 
curve so that protein samples with suitable concentration could be prepared for 
subsequent protein electrophoresis. 
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2.3,2.4.3 Protein Electrophoresis 
After protein assay, the concentration of each protein sample was calculated. 
25iLig protein samples were diluted and prepared in IX sample buffer (including 
62.5mM Tris-base, 10% w/v glycerol, 10% 2-mercaptoethanol, 2.3% SDS and 
bromophenol blue, pH6.8). Then, those protein samples could then be resolved in the 
polyacrylamide gel electrophoresis. Dependent on the molecular weight of the desired 
signaling molecules, different percentage of lower gel and upper stacking gel were 
prepared accordingly; 8% for high molecular weight proteins and 12-15% for low 
molecular weight proteins. For the lower nmning gei solution, it was prepared by 
mixing suitable volume of corresponding percentage of acrylamide lower gel mix 
(including 40% acrylamide, 4X lower gel buffer�containing 0375M Tris-base and 
0.1% SDS, pH8.8> and distilled water) with TEMED and 10% ammonium persulfate. 
On the other hand, for the upper stacking gel solution, it was prepared by mixing 
suitable volume of 4.5% upper gel mix (including 40% acrylamide, 4X upper gel 
buffer�containing 0.125M Tris-base and 0.1% SDS, pH6.8> and distilled water) with 
TEMED and 10% ammonium persulfate. After that, the gels were allowed to set in the 
Mini-PROTEAN® II gel electrophoresis apparatus. The diluted protein samples were 
then loaded onto the gels and run in IX SDS running buffer (including 25mM 
Tris-base, 0.19M glycine and 0.1% SDS, pH6.8) at 200V for about 45 minutes. 
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2.3.2.4.4 Electroblot (Protein Transfer) 
After protein samples were resolved on the gels during gel electrophoresis, the 
gels were then removed for subsequent electroblotting in order to transfer the proteins 
from the gels to the immobilon-P transfer membrane. First of all, thick blotter papers 
(2 pieces per gel) were soaked in electroblot transfer buffer (including 25mM 
Tris-base, 0.19M glycine, 15% methanol and distilled water) and then placed onto the 
platinum anode of the TransBlot® SD Semi-Dry Transfer Cell. Moreover, the 
Immobilon-P transfer membrane was first wet in 100% methanol for 1-2 seconds and 
then soaked in Electroblot transfer buffer for further 5 minutes. Then, the equilibrated 
membrane was placed onto the blotter paper. Next, the gel was rinsed in the 
electroblot transfer buffer and placed on the top of the membrane with the same 
orientation. Finally, another piece of thick blotter paper was soaked in the Electroblot 
transfer buffer and then placed onto the gel. The stainless steel cathode was placed 
onto the stack. Air bubbles should be avoided during the whole protein transfer 
process. After that, it was proceeded at 15V for 30 to 40 minutes so that the blotted 
proteins were transferred from the gel to the membrane which was then used for 
further antibody probing. 
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2.3.2.4.5 Antibody Probing (Immunoblotting) 
After the proteins were transferred to the Immobilon-P transfer membrane, it 
was used for desired antibody probing. First, those membranes were immersed in 
methanol for 10 seconds and then into IX PBS for 1-2 seconds. Then, membranes 
were incubated with 5% non-fat dry milk in a square petri-dish at 4®C overnight for 
blocking the membranes. Next day, milk was poured away and membranes were 
washed and rocked three times with PBS-T buffer (IX PBS + 0.1% Tween 20) for 10 
minutes. The washing step was then repeated once again. Then, membranes were 
drained and incubated with 3ml of the desired diluted primary antibody for 2 hours at 
room temperature followed by gentle rocking. After that, the unbound primary 
antibody was washed away and rocked three times by IX PBS-T buffer for 10 
minutes. Membranes were then drained and incubated with 5ml of the diluted 
horseradish peroxidase conjugated secondary antibody (anti-mouse, anti-rabbit or 
anti-goat antibody) for 1 hour at room temperature with gentle rocking. Afterwards, 
the unbound secondary antibody was washed away three times with IX PBS-T buffer 
for 15 minutes. Subsequently, the corresponding protein expression signals were 
detected by ECL (Enhanced Chemiluminescence) Western Blotting Detection 
Reagents. Equal volume of (2ml respectively) of Detection Reagent 1 and 2 were 
mixed in a square petri-dish first. Then, membranes were rinsed in the mixed reagent 
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and incubated for exactly 1 minute at room temperature with gently mixing by hand. 
Later, membranes with protein side up were drained and laid in transparency. It was 
ensured that no air-bubbles existed in order to prevent the disturbance of the signal 
development. Finally, the membranes were placed in the film cassette and exposed to 
the X-ray film so that the signals can be developed on the X-ray film. After that, 
Kodak Digital Science software was used for quantification of the intensity of each 
protein band for further comparison between different cell lines afterwards. 
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2.4 Results 
2.4.1 Growth Curve 
To study the effect of EGF on the growth of A431 parent cells and 
EGF-conditioned cells, the growth curve of two cell lines were examined by MTT 
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Figure 2.20 The comparison of the growth between the A431 parent cells and 
EGF-coiiditioned cells. It is drawn in a semi-log scale. The X-axis 
refers to the day of the experiment; the Y-axis refers to the number of 
cells in logarithmic scale. The error bar is the standard deviation from 
three different sets of experiments under the same condition. AP 
refers to A431 parent cells and AC refers to EGF-conditioned cells. 
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2.4.2 EGF Responses of A431 Parent Cells and EGF-conditioned 
Ceils by MTT Assay 
The sensitivity to EGF of A431 parent cells and EGF-conditioned cells was 
examined by MTT assay and shown in Figure 2.21. According to Figure 2.21, it 
showed that the response to EGF in two cells lines was completely different. EGF 
inhibited the growth of A431 parent cells, but stimulated the growth of the 
EGF-conditioned cell. At the concentration of lOng/ml EGF, the percentage of 
survival in A431 parent cells and EGF-conditioned cells was 30% and 150% 
respectively. At the concentration of 50ng/ml EGF, the percentage of survival in 
parent cells and conditioned cells was 25% and 170% respectively. In the subsequent 
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Figure 2.21. The sensitivity to EGF of A431 parent cells and 
EGF-conditioned cells that were examined by MTT assay. 
AP refers to A431 parent cells and AC refers to 
EGF-conditioned cells. The error bar is the standard derivation 
from three different sets of experiments in the same condition. 
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2.4.3 The EGFR Expression Levels in A431 Parent Cells and 
EGF-conditioned Cells by Western Blot Analysis 
As mention before, differential sensitivity to EGF was found in A431 parent cells 
and EGF-conditioned cells respectively. EGF specifically bound to its receptor ---
EGFR to exert its own biological effects in the cell. Therefore, to further study the 
reason contributed to differential sensitivity pattern to EGF in two cell lines, EGFR 
expression level was first measured to see whether the differential response to EGF 
was due to various degree in the EGFR level in two cell lines or not. 
The EGFR expression in A431 parent cells and EGF-conditioned cells was 
studied by Western Blot analysis using antibody against EGFR. The molecular weight 
of EGFR is 170kDa. The basal level of EGFR in two cell lines was shown in Figure 
2,22. As shown in Figure 2.22, it was found that the expression level of EGFR in two 
cell lines was nearly the same. Therefore, it seemed that the differential responses of 
these two cell lines to EGF were unlikely related to the EGFR. 
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Figure 2.22. The basal expression level of EGFR in A431 parent cells and 
EGF-conditioned cells by Western Blot analysis probing with 
the mouse polyclonal anti-EGFR antibody. AP refers to A431 
parent cells and AC refers to EGF-conditioned cells. The numbers 
beneath each protein band are the relative expression ratio of the 
protein in the EGF-conditioned cells in relation to that in A431 
parent cells. The value is the averages of data obtained from three 
to four different sets of experiments. 
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2.4.4 EGF-induced Protein Tyrosine Phosphorylation Pattern in A431 
Parent Cells and EGF-conditioned Cells by Western Blot 
Analysis 
The EGF-induced protein tyrosine phosphoryation pattern in A431 parent cells 
and EGF-conditioned cells was studied in order to examine whether the differential 
response to EGF in two cell lines was due to the presence of non-functional EGFR in 
any one of these cell lines. After binding to EGFR, EGF activated EGFR and induced 
EGFR dimerization and autophosphorylation, and then initiated cascades of 
phosphorylation of multiple signal transduction molecules. As a result, the protein 
tyroine phosphorylation profile in A431 parent cells and EGF-conditioned cells was 
investigated by Western Blot analysis by using antibody against phosphotyrosine 
(PY20). If a series of tyrosine phosphorylated proteins was detected, the EGFR in that 
cell line was indicated to be functional. 
As shown in Figure 2.23, it clearly showed that there was a group of proteins 
undergone tyrosine phosphoylation upon incubation with 50ng/ml EGF and the 
pattern was similar between A431 parent cells and EGF-conditioned cells. The results 
suggested that the EGFR in both two cell lines were functional. 
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Figure 2.23. The tyrosine phosphorylated proteins profile in A431 parent cells 
and EGF-conditioned cells by Western Blot analysis. The cells 
were incubated with 50ng/ml EGF for up to 48 hours and lysed for 
Western Blot analysis. The proteins were then probed with mouse 
monoclonal anti-phosphotyrosine (PY20) antibody. AP refers to 
A431 parent cells and AC refers to EGF-conditioned cells. “-“ means 
no EGF added in the cells and ‘‘+” means 50ng/ml was added in the 
cells. 
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2.4.5 The Expression Profiles of EGFR Signaling Molecules in A431 
Parent Ceils and EGF-conditioned Cells by Western Blot 
Analysis 
According to the previous experimental results, the differential in responses to 
EGF which shown inhibitory effect on A431 parent cells and stimulatory effect on 
EGF-conditioned cells seemed not to correlate with the basal level and activity of 
EGFR. One may speculate that the EGFR downstream signaling may contribute to the 
differential sensitivity to EGF in these two cell lines. Thus, the protein expression 
levels of some of the signaling molecules involved in the EGFR signaling were 
compared between A431 parent cells and EGF-conditioned cells by Western Blot 
Analysis. 
As mention before, there are three main intracellular downstream signal 
transduction pathways involved in EGFR signaling. They are the Ras/Raf/MAPK 
pathway, the Jak/Stat pathway and the PBK/Akt pathway. These multiple signaling 
pathways interact and generate a highly complicated network to modulate various 
cellular processes, including cell proliferation, survival, migration and differentiation. 
The experimental results for the differential expression levels of the signaling 
molecules were shown in Figure 2.24-2.26 and summarized in Table 2.3. 
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2.4.5.1 The Ras/Raf/MAPK Pathway 
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Figure 2.24. The expression levels of signaling molecules involved in the Ras/Raf/MAPK 
pathway in A431 parent cells and EGF-conditioned cells by Western Blot 
Analysis. The numbers beneath each protein band are the relative expression 
ratio of the protein in the EGF-conditioned cells in relation to that in A431 
parent cells. The value is the averages of data obtained from three to four 
different sets of experiments. AP refers to A431 parent cells and AC refers to 
EGF-conditioned cells. 
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2.4.5.2 The Jak/Stat Pathway 
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Figure 2.25. The expression levels of signaling molecules involved in the Jak/Stat pathway in 
A431 parent cells and EGF-conditioned cells by Western Blot Analysis. The 
numbers beneath each protein band are the relative expression ration of the protein in 
the EGF-conditioned cells in relation to that in A431 parent cells. The value is the 
averages of data obtained from three to four different sets of experiments. AP refers to 
A431 parent cells and AC refers to EGF-conditioned cells. 
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2.4.5.3 The PI3K/Akt Pathway 
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Figure 2.26. The expression levels of PI3K that is involved in the PI3K/Akt 
pathway in A431 parent cells and EGF-conditioned cells by Western 
Blot Analysis. The numbers beneath the protein band is the relative 
expression ratio of the protein in the EGF-conditioned cells in relation to 
that in A431 parent cells. The value is the averages of data obtained from 
three to four different sets of experiments. AP refers to A431 parent cells 
and AC refers to EGF-conditioned cells. 
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Signaling Molecules Molecular Weight Protein Expression Levels 
OThe Ras/Raf/MAPK pathway, 
^ 21 kPa A P < A C  
Raf-1 77 kPa AP>AC  
MEK-1 45 kPa AP>AC  
ERK 
ERKl (p44) 44 kDa AP>AC 
ERK2 (p42) 42 kPa AP > AC 
JNK-1 46 kDa AP > AC 
©The Jak/Stat pathway, 
J ^ 130 kDa AP < AC 
Jak2 131 kDa AP< AC 
Jak3 120 kPa A P > A C  
Tyk2 135 kPa A P < A C  
Statl 84/91 kPa AP < AC 
Stat2 113 kPa A P < A C  
Stat3 92 kPa AP �A C 
stats 83 kDa AP~AC 
©The PBK/Akt pathway,  
PI3K 80 kDa AP �A C 
Table 2.3. Summary of the protein expression levels of various signaling 
molecules involved in the three major EGFR intracellular 
signaling pathways (including the Ras/Raf/MAPK pathway, the 
Jak/Stat pathway and the PI3K/Akt pathway) in A431 parent cells 
and EGF-conditioned cells. "< ” refers to “hwer,, level; “ > ” refers 
to “higher” level; “ � “ refers to “similar” level. AP refers to A431 
parent cells and AC refers to EGF-conditioned cells. 
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First of all, for the Ras/Raf/MAPK pathway, several critical molecules were 
investigated. They were Ras, Raf-1, MEK-1, MAPKs (including ERKl, ERK2, 
JNK-1 and p38). By Western Blot Analysis, the expression levels of these signaling 
molecules in A431 parent cells and EGF-conditioned cells were compared. As shown 
in Figure 2,24, the expression levels of Raf-1, MEK-1, MAPKs were higher in A431 
parent cells than that in the EGF-conditioned cells, except the level of Ras that was 
higher in the EGF-conditioned cells. The levels of Raf-1, MEK-1 and JNK-1 were 
about 2-folded greater in A431 parent cells than in EGF-conditioned cells while the 
levels of ERKs and p38 were only slightly higher in A431 parent cells than that in the 
EGF-conditioned cells. 
Secondly, for the Jak/Stat pathway, the levels of several Jaks (including Jakl, 
Jak2, Jak3 and Tyk2) and several Stats proteins (including Statl, Stat 2, Stat3, StatS 
and ISGF-3y) were studied. As shown in Figure 2.25, it revealed contrary results to 
that of the Ras/Raf/MAPK pathways. Mostly, the expression levels of the signaling 
molecules involved in the Jak/Stat pathway seemed to be higher in the 
EGF-conditioned cells than that in the A431 parent cells. Moreover, among the Jaks 
and Stats molecules, Statl and Stat2 were 3-folded higher in EGF-conditioned cells 
than that in A431 parent cells. In addition, ISGF-3y had 2.5-folded higher expression 
in EGF-conditioned cells also. In the case of Jakl, Jak2, Jak3 and Tyk2, about 
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L5-folded higher expression was detected in the EGF-conditioned cells. Whereas, for 
Stat3 and Stat 5, the expression levels of these two signaling molecules seemed to be 
similar between two cell lines. 
Finally, for the PI3K/Akt pathway, only the expression level of PI3K was 
examined. According to Figure 2.26, it was shown that the expression level of PI3K 
in A431 parent cells was similar than that in the EGF-conditioned cells. 
As a result, it is indicated that the EGFR signaling (mainly the Ras/Raf/MAPK 
pathway and the Jak/Stat pathway) in the EGF-conditioned cells has been altered. 
Further investigations were therefore carried out to study the relationship between the 
alteration of EGFR signaling and the differential growth responses to EGF in these 
two cells lines. 
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2.4.6 The Cellular Responses to the Modifiers that Targeting the 
EGFR Signaling 
To examine the relationship between the alteration in EGFR signaling and EGF 
induced growth response in EGF-conditioned cells, a series of different signaling 
modifiers that targeting at different molecules involved in EGFR signaling pathways 
(mainly include the EGFR itself, the Ras/Raf/MAPK pathway and the Jak/Stat 
pathway) were employed to see if they can modify the EGF related growth effect 
accordingly. Therefore, in this part, the responses of A431 parent cells and 
EGF-conditioned cells to these EGFR signaling modifiers were studied by MTT 
assay. 
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2.4.6.1 The Sensitivity of A431 Parent Cells and EGF-conditioned Cells to 
Various EGFR Signaling Modifiers 
Before studying the responses of A431 parent cells and EGF-conditioned cells to 
the combination of different signaling modifiers and EGF, the toxicity of the 
modifiers on A431 parent cells and EGF-conditioned cells should first be found out. 
The sensitivity of A431 parent cells and EGF-conditioned cells to the signaling 
modifiers were shown in Figure 2.27-230 and summarized in Table 2.4. The 
signaling modifiers include tyrphostin A25 (EGFR inhibitor), L744832 (Ras inhibitor), 
ZM336372 (Raf inhibitor), PD98059 (MEK inhibitor), Apigenin (ERKs inhibitor), 
SB203580 (p38 inhibitor), Jak inhibitor 1 (Jaks inhibitor), AG490 (Jak2 inhibitor) and 
LY294002 (PI3K inhibitor). Overall speaking, the sensitivity of both cell lines to all 
there signaling modifiers were similar. 
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Tyrphostin A25 (EGFR inhibitor) 
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Figure 2.27. The responses of A431 parent cells and EGF-conditioned cells to 
tyrphostin A25 (EGFR inhibitor) as measured by MTT assay. The 
cells were incubated with the inhibitor for 5 days. AP (the blue line) 
refers to A431 parent cells and AC (the pink line) refers to 
EGF-conditioned cells (AC). The experiments have been repeated 
twice and results from both experiments were similar. The one shown is 
the most representative one. 
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SB203580 (p38 inhibitor) 
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Figure 2.28. The responses of A431 parent cells and EGF-conditioned cells to various 
signaling modifiers involved in the Ras/Raf/MAPK pathway as measured 
by MTT assay. The signaling modifiers include L744832 (Ras inhibitor), 
ZM336372 (Raf inhibitor), PD98059 (MEK inhibitor), Apigenin (ERKs 
inhibitor) and SB203580 (p38 inhibitor). The cells were incubated with the 
inhibitors for 5 days. AP (the blue line) refers to A431 parent cells and AC (the 
pink line) refers to EGF-conditioned cells (AC). The experiments have been 
repeated twice and results from both experiments were similar. The one shown 
is the most representative one. 
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Figure 2.29. The responses of A431 parent cells and EGF-conditioned cells to various 
signaling modifiers involved in the Jak/Stat pathway as measured by 
MTT assay. The signaling modifiers include Jak inhibitor 1 (Jaks inhibitor) 
and AG490 (Jak2 inhibitor). The cells were incubated with the inhibitors for 
5 days. AP (the blue line) refers to A431 parent cells and AC (the pink line) 
refers to EGF-conditioned cells (AC). The experiments have been repeated 
twice and results from both experiments were similar. The one shown is the 
most representative one. 
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Figure 2.30. The responses of A431 parent cells and EGF-conditioned cells to 
LY294002 (PI3K inhibitor) as measured by MTT assay. The cells 
were incubated with the inhibitors for 5 days. AP (the blue line) refers 
to A431 parent cells and AC (the pink line) refers to EGF-conditioned 
cells (AC). The experiments have been repeated twice and results from 
both experiments were similar. The one shown is the most 
representative one. 
74 
Signaling Modifiers Concentration IC50 Targets 
Tyrphostin A25 5 |LIM 7 |AM E G F R 
OThe Ras/Raf/MAPK pathway, 
L744832 20 i^M / Ras 
ZM336372 6 [iM 2 juM Raf 
PD98059 25 |LIM 2 |LIM MEK 
Apigenin 10 |LIM 12.5 |LIM ERKs 
SB203580 15 i^M 600 nM p38 
@The Jak/Stat pathway, 
Jak inhibitor 1 2 |aM 1-15 nM Jaks 
A G 4 9 0 25 |LIM 100 nM Jak2 
�T h e P13K7Akt pathway,  
LY294002 10 j^ M 5 i^M PI3K 
Table 2.4. Summary of the detailed information and working concentrations 
about each signaling modifiers related to EGFR, the Ras/Raf/MAPK 
pathway, the Jak/Stat pathway and the PI3K/Akt pathway. The IC50 
of each modifier were found from the drug information sheet provided by 
the company. 
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2.4.6.2 The Influence of EGFR Signaling Modifiers on EGF 
Based on the dose response curve of the of A431 cells, the combinations of the 
signaling modifiers to be used in the combination treatment study at which the 
concentrations showed significant differences in toxicity between A431 parent cells 
and EGF-conditioned cells were selected. Detailed information of the working 
concentrations of the signaling modifiers was summarized in Table 2,5. 
As stated before, EGF can inhibit the growth of A431 parent cells, but have a 
stimulatory effect on EGF-conditioned cells. Furthermore, the results also indicated 
that the expression patterns of the critical EGFR signaling molecules were different in 
two cell lines. One interesting phenomenon was discovered that the expression 
profiles of the signaling molecules involved in the Ras/Raf/MAPK pathway exhibited 
a totally contrary pattern than that in the Jak/Stat pathway. The results revealed that in 
the Ras/Raf/MAPK pathway, the expression levels of the majority of the signaling 
molecules in A431 parent cells were higher than that in the EGF-conditioned cells. 
However, in the Jak/Stat pathway, most of the signaling molecules were higher in 
EGF-conditioned cells. 
In the subsequent experiments, the influences of the signaling modifiers 
targeting at different molecules of EGFR signaling on the EGF related growth effect 
in A431 parent cells and EGF-conditioned cells were studied. The results were shown 
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in Figure 2,31-233. 
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Figure 2.31. The influence of the EGFR inhibitor, tyrphostin A25, on EGF related 
growth effect in A431 parent cells and EGF-conditioned cells as measured 
by MTT assay. The error bar is the standard derivation from three or more 
different sets of experiments�AP refers to A431 parent cells and AC refers to 
EGF=conditioned cells. The blue line represents the treatment in the absence 
of the signaling modifier; the pink line represents the treatment in the presence 
of the signaling modifier. The survival for treatment with combination of EGF 
and modifiers had already been normalized by the toxicity of the modifiers 
used. 
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PD98059 (MEK inhibitor) + EGF 
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SB203580 (P38 inhibitor) + EGF 
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Figure 2.32. The influences of signaling modifiers targeting at the Ras/Raf/MAPK 
pathway on EGF related growth effect in A431 parent cells and 
EGF-conditioned cells as measured by MTT assay. The signaling modifiers 
include L744832 (Ras inhibitor), ZM336372 (Raf inhibitor), PD98059 (MEK 
inhibitor), Apigenin (ERKs inhibitor) and SB203580 (p38 inhibitor). The error 
bar is the standard derivation from three or more different sets of experiments. 
AP refers to A431 parent cells and AC refers to EGF-conditioned cells. The 
blue line represents the treatment in the absence of signaling modifier; the pink 
line represents the treatment in the presence of signaling modifier. The survival 
for treatment with combination of EGF and modifiers had already been 
normalized by the toxicity of the modifiers used. 
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AG490 (Jak2 inhibitor) + EGF 
AP AC 
100 I t 120 L i 
_ _ 
I \ ^ ^ I ® ^ 
40 
20 ^ 20 1 
I : 
Q 1 1 1 1 1 1 Q I I i I I I 
0 20 40 60 80 100 0 20 40 60 80 100 
Concentration (ng/ml) Concentration (ng/ml) 
Figure 2.33. The influence of the Jak2 inhibitor, AG490, targeting at the Jak/Stat 
pathway on EGF related growth effect in A431 parent cells and 
EGF-conditioned cells as measured by MTT assay. The error bar is the 
standard derivation from three or more different sets of experiments. AP refers 
to A431 parent cells and AC refers to EGF-conditioned cells. The blue line 
represents the treatment in the absence of signaling modifier; the pink line 
represents the treatment in the presence of signaling modifier. The survival for 
treatment with combination of EGF and modifiers had already been 
normalized by the toxicity of the modifiers used. 
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First of all, the influence of EGFR inhibitor，tryphostin A25, on EGF related 
growth effect in A431 parent cells and EGF-conditioned cells was shown in Figure 
231. It revealed that the inhibition seemed to have no effect on the EGF related cell 
growth in both two cell lines. 
Secondly, for the Ras/Raf/MAPK pathway, several signaling modifiers were 
used. They were L744832 (Ras inhibitor), ZM336372 (Raf inhibitor), PD98059 
(MEK inhibitor), apigenin (ERKs inhibitor) and SB203580 (p38 inhibitor). The 
influences of theses signaling modifiers on the differential EGF growth effect in A431 
parent cells and EGF-conditioned cells were shown in Figure 232. The Ras inhibitor, 
L744832, increased the related growth effect in both A431 parent cells and 
EGF-conditioned cells, i.e., the inhibitory and stimulatory effect of EGF in A431 
parent cells and EGF-conditioned cells respectively were enhanced in the presence of 
Ras inhibitor. However, the other signaling modifiers appeared not to affect the EGF 
growth suppression effect in A431 parent cells but increased the EGF growth 
stimulation effect in EGF-conditioned cells. 
Thirdly, for the Jak/Stat pathway, the influence of the Jak2 inhibitor, AG490 on 
EGF related growth responses in A431 parent cells and EGF-conditioned cells was 
examined. The results were shown in Figure 2.33. In the presence of Jak2 inhibitor, 
the EGF growth suppression effect was significantly enhanced in A431 parent cells 
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Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase (RTK) 
that consists of the intrinsic tyrosine kinase activity in its intracellular domain. 
Over-expression of EGFR is a common phenomenon in a wide variety of human 
cancers, including non-small cell lung (NSCL), head and neck，breast, bladder and 
ovarian carcinomas. (Levitzki, 1994; Powis, 1994; Levitzki, 1997). Moreover, many 
studies have been indicated that the elevated expression level of EGFR is directly 
associated with disease progression, poor survival, poor response to therapy and 
development of drug resistance. (Salomon et al, 1995). 
After the binding of ligand (e.g.: EGF) to EGFR, the receptor becomes activated 
and thus trigger multiple signaling pathways, including the Ras/Raf/MAPK pathway, 
the Jak/Stat pathway and the PBK/Akt pathway. {Wells, 2000). These pathways 
interact with each other and generate an extremely complicated networks to regulate 
many important cellular functions, including cell survival, apoptosis, angiogenesis, 
mitogenesis and metastasis, etc. {Rusch et al, 1996; Rusch et al, 1997). Many 
evidences support that aberration of any components in EGFR signaling will result in 
initiating and sustaining of uncontrolled growth and metastasis of tumor cells. {Porter 
and Vaillancourt, 1998; Stern, 2000). As a result, EGFR and its downstream signal 
transduction pathways have become an attractive target for the development of novel 
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strategy in recent cancer therapy. {Woodburn, 1999; Basalga, 2000). 
In the present study, the EGF-conditioned cells were established by chronic 
exposure of A431 parent cells to EGF continuously. After that, the cellular responses 
to EGF in A431 parent cells and EGF-conditioned cells were compared. As we all 
know that, EGF is a potent mitogen for a number of cell types in cell culture or in vivo. 
But, the A431 cell line expresses an unusually large number of high affinity cell 
membrane receptor (EGFR) for EGF. {Fabricant et al,1977; Haigler et al, 1978). 
Evidences also revealed that A431 cells were growth-inhibited by EGF because EGF 
can induce a G1 cell cycle block with an inhibition of CDK2 by the inhibitor 
p21/CIP/WAFl in A431 cells. {Fan et al, 1995). By MTT assay, EGF was found to 
inhibit the growth of A431 parent cells while a stimulatory effect is observed by EGF 
in the EGF-conditioned cells by EGF. This differential growth effect to EGF between 
A431 parent cells and EGF-conditioned cells were believed to be related to the 
outcome of its alteration in signaling pathways while such correlation is still not fully 
understood. (Barne, et al, 1982; Konger and Chan, 1993; Davis and Chamberlin, 
1996; Luca et al, 1997; Aigner et al, 2000). 
By Western Blot analysis, it indicated that the expression profiles of various 
signaling molecules involved in the three major EGFR signal transduction pathways 
(including the Ras/Raf/MAPK pathway, the Jak/Stat pathway and the PBK/Akt 
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pathway) were different between the two cell lines. Interestingly, for the 
Ras/Raf/MAPK pathway, the expression levels of most of the signaling molecules 
were shown to be higher in A431 parent cells than that in the EGF-conditioned cells; 
however; for the Jak/Stat pathway, the signaling molecules were at higher level in 
EGF-conditioned cells than that in A431 parent cells. So, it could prove that the 
signaling in EGF-conditioned cells was indeed changed. 
A hypothesis is generated to explain the differential EGF growth responses and 
it is shown in Figure 2,34. After the specific binding of EGF to EGFR, it can initiate a 
multiple signaling cascade within the cells, including the Ras/Raf/MAPK pathway 
and the Jak/Stat pathway. Normally, A431 parent cells which had higher expression of 
Raf, MEK-1 and ERKs and lower expression of Jaks and Stats than EGF-conditioned 
cells {Table 2,4) will prefer the Ras/Raf/MAPK pathway than the Jak/Stat pathway, so 
that the inhibitory growth response to EGF was observed. However, chronic 
EGF-conditioning treatment can modify the signaling equilibrium between the 
Ras/Raf/MAPK pathway and the Jak/Stat pathway. So, upon exposure to EGF, the 
cells will prefer the Jak/Stat pathway rather than the original Ras/Raf/MAPK pathway. 
As a result, different cellular responses of EGF-conditioned cells to EGF were found, 
i.e., growth stimulation in EGF-conditioned cells. The hypothesis is further supported 
by the results for the signaling modifiers experiments. The signaling modifiers in the 
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RaCMAPK pathway primarily did not affect the EGF growth suppression in A431 
parent cells which had higher expression of Raf-1, MEK-1 and ERKs (Table 2.4) 
while the MEK and ERK inhibitors enhanced the EGF stimulation effect in 
EGF-conditioned cells. In the case of the Jak/Stat pathway, the modifier however 
enhanced the growth suppression effect in A431 parent cells which had reduced levels 
of Jaks and Stats {Table 2.4) but did not affect the growth stimulation effect in 
EGF-conditioned cells. Since the EGFR signaling is an extremely complicated 
network in cells so that the detailed mechanisms contributed to this shifting in the 
equilibrium between the Ras/Raf/MAPK pathway and the Jak/Stat pathway is not 
fully understood. Therefore, it is very difficult to make a conclusion in this aspect now. 
Further identification that can focus on more specific mechanisms about the outcome 
of the prolonged EGF-conditioning treatment should be needed in order to study this 
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Figure 2.34. The hypothesis about the shifting of the signaling equilibrium after 
the treatment of EGF-conditioning so that it causes the differential 
growth responses to EGF in A431 cells. 
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Chapter 3 
The Inter-Relationship between 
the Differential Anti-cancer Drugs 
Sensitivity and Alteration of 
EGFR Signaling in 
EGF-conditioned A431 Cells 
3.1 Background Information 
3.1.1 Drug Resistance and its Mechanisms in Tumor Cells 
In traditional cancer therapy, surgery, chemotherapy and radiotherapy are 
standard treatments for cancer patients. However, these therapies usually give 
significant side-effects to patients at the same time. Especially, for chemotherapy, 
drug resistance is a major cause of ineffectiveness in chemotherapeutic treatment of 
human malignancies. (McKenna and Padua, 1997). Mostly, tumor cells will not be 
resistant just against one anticancer drug. Tumor cells can be cross-resistant to a wide 
variety of structurally and functionally unrelated anticancer drugs and the resistance is 
termed as multi-drug resistance (MDR). (McCIean and Hill, 1992). 
In fact, there are two general classes of drug resistance, including intrinsic 
resistance and acquired resistance. Intrinsic resistance refers to a tumor that is totally 
insensitive to the cytotoxic drug. Acquired resistance refers to a tumor that is 
previously chemosensitive, but progressively become resistant to the cytotoxic drug 
due to continuously exposure to the same drugs and this kind of resistance often arise 
from chemotherapy. 
In the case of acquired resistance, there are various cellular mechanisms 
contribute to this phenomenon. {Figure 3.1). First, some drugs efflux proteins, such as 
P-glycoprotein (Pgp), MDR-associated protein (MRP), etc can decrease drug 
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accumulation in cells so that the antitumor activity of the drugs were eliminated. 
Overexpression of Pgp is detected in a broad range of human malignancies, such as 
leukemia, breast cancer, lung cancer, neuroblastoma, etc. (Linn et al, 1997). In 
addition, activation of the glutathione detoxification system can also lower the 
intracellular concentration of anticancer drugs. The process of detoxification can be 
catalyzed by the enzyme --- glutathione-S-transferase (GST). Evidences show that 
elevated levels of glutathione as well as enhanced activity of GST were found in 
various human tumor cell lines. (Zhang et al, 1998). Moreover, enhanced DNA repair 
is also a common drug resistance mechanism. For instance, experimental data 
implicated that mismatch repair deficiency is correlated to resistance to a wide range 
of anticancer agents, including cisplatin and doxorubicin. {Brown et al, 1997). Apart 
from these, defective apoptosis can contribute to the occurrence of drug resistance in 
tumor cells as well. Normally, cell survival and cell death are balanced by a number 
of regulator molecules at multiple levels; however, any defective of these apoptotic 
responses can lead to the development of drug resistance in tumor cells. (Kaufmann et 
la., 2000). These cellular drug resistance mechanisms are usually operated in tumor 
cells simultaneously and they are inter-connected in most cases. 
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Figure 3.1. The summary of four common cellular mechanisms of drug 
resistance in tumor cells, 
(modified from Michael and Susan, 2002) 
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3.1.2 Anti-cancer Drugs — Introduction 
3.1.2.1 Camptothein (CPT) 
Camptothecin (CPT) is a cytotoxic alkaloid that is isolated from Camptotheca 
acuminate (Nyssaceae), a tree found in China. The chemical structure of camptothecin 
is shown in Figure 3.2 
CPT is a topoisomerases-targeting anticancer drug (topoisomerase poison). It can 
specifically target DNA topoisomerase I (Topo I). For example, experiments showed 
that camptothecin sensitivity was directly related to topoisomerase I concentration in 
tumor cell lines. (Sugimoto et al.’ 1990). DNA topoisomerases are important nuclear 
enzymes that can solve the topological problems of DNA during many essential 
cellular processes, including DNA replication, RNA transcription, mitosis, 
chromosome condensation etc. (Nitiss, 199S). 
9 ； 
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n �产 、 :I：, L Figure 3.2. The chemical structure of Camptothecin (CPT). 




Normally, Topo I binds to the locally unwound supercoiled DNA and then 
reversibly introduces a nick in one of the DNA strand. Then the single-strand break 
can be stabilized by the formation of a covalent DNA-protein phosphodiester bonds 
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between the ends of the broken DNA strand and a tyrosine residue of Topo L {Stewart 
et al, 1988). Topo I can then reseal the DNA break by passing the intact strand 
through the break and then dissociate from the DNA strand finally so that the DNA 
with one negative supercoil can be removed. However, in the presence of CPT, the 
drug can bind to Topo I and DNA simultaneously and form a stable ternary complex. 
As a result, this complex cannot proceed the original resealing step in the 
strand-passing reaction. After that, when the CPT-stabilized covalent complex collides 
with the DNA replication machinery, the single-strand breaks will be converted into 
irreversible double-strand breaks so that apoptosis is induced and DNA replication is 
inhibited also. (Hsiang et al, 1989; Hsiang et al, 1995). Moreover, due to the 
selective Topol poisoning effect of CPT, CPT exerts their cytotoxicity predominantly 
in S-phase in tumor cells. (Del Bino et al, 1991). The mechanism of the CPT action is 
shown in Figure 3.3. 
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Figure 3.3. The schematical description of the mechanism of camptothecin (CPT) 
action on topoisomerase I (Topo I). Originally, Topol (E) binds to the 
supercoiled DNA and introduces a nick on one of the DNA strand. The 
single-stranded break is then stabilized by the formation of a DNA-protein 
covalent phosphodiester bond. But, in the presence of CTP (D), it can bind 
to Topol and DNA simultaneously and generate a ternary complex so that it 
cannot progress to the normal resealing step of the strand-passing reaction. 
Hence, when this ternary complex collides with the DNA replication fork, 
DNA replication is inhibited and no DNA synthesis can be made, 
(from Topcu, 2001) 
3.1.2.2 Methotrexate (MTX) 
Methotrexate (MTX) is a classical antifolate drug that is structurally similar to 
folic acid. MTX has been widely used for treatment of a number of malignancies, 
including leukemia, lymphoma, head and neck cancer, osteogenic sarcoma, etc. 
Furthermore, it is also used for treatment of various non-malignant diseases, such as 
rheumatoid arthritis, psoriasis and in the prevention of graft versus host disease after 
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transplantation. {Gorlick et al, 1996). {Figure 3.4). 
Nil： (f f~\ j| p'OH 
[(_) ( ] \ � Figure 3.4. The chemical structure of methotrexate (MTX). 
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The primary cellular target of MTX is dihydrofolate reductase (DHFR). DHFR is 
an important enzyme involved in intracellular folate metabolism that can regenerate 
tetrahydrofolate from dihydrofolate by catalyzing the reduction of folate and 7,8 
dihydrofolate to 5,6,7,8 tetrahydrofolate in the presence of NADPH. (Bertino, 1993). 
Tetrahydrofolates can then be converted into a variety of other reduced-folate 
coenzymes that play essential role in the single-carbon transfer reactions involved in 
DNA, RNA and protein biosynthesis. 
In order to competitively inhibit DHFR, first of all, MTX entered the cells 
primarily by an active carrier transport mechanism that is mediated by the reduced 
folate carrier (RFC). Once inside the cell, intracellular MTX is then metabolized to 
polyglutamate derivatives by the enzyme — folypolyglutamate synthetase (FPGS) 
that sequentially adds glutamate residues (up to five) to MTX for its retention in cells. 
{McGuire et al, 1980; Whitehead et al, 1990). MTX and polyglutamated forms of 
MTX are tight inhibitor of DHFR so that it can disturb pyrimidine (thymidylate) 
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biosynthesis. In addition, MIX polyglutamates and dihydrofolate polyglutamates are 
also inhibitors of enzymes that are participated in purine biosynthesis. (Jolivet et al, 
1983; Allegra et al, 1985). As a result, no DNA synthesis can be synthesized in cells 
any more. On the other hand, the removal of glutamate residues from the 
polyglutamated forms of both folates and MTX is mainly catalyzed by the enzyme … 
gamma glutamyl hydrolase (GGH). In normal, this enzyme and FPGS maintain a 
balance between the polyglutamated and glutamated forms of folates and MTX in 
order to ensure the accumulation of polyglutamated MTX in tumor cells. {Wang et al, 
1986). 
Indeed, there are several mechanisms contributed to MTX resistance in tumor 
cells. The first mechanism is defective transport of MTX. It is also the most common 
resistance mechanisms to MTX. Any mutation or decreased level of RFC may 
contribute to MTX resistance. For example, according to complementary DNA study 
of RFC, it indicates that there is a strong correlation between low level of RFC 
expression and the impaired MTX intake. {Gorlick et al, 1997). The second 
mechanism is related to the MTX target --- DHFR. Any DHFR gene amplification or 
mutation will contribute to resistance to MTX in cells. For instance, based on some 
clinical researches, DHFR gene amplification was proved to be associated with 
acquired MTX resistance in patient samples. {Goker et al, 1995). The third 
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mechanism is contributed by the defective polyglutamation of MIX. Lack of 
accumulation of MTX polyglumates may be due to the impaired activity of FPGS or 
due to the increased breakdown of polyglumated MTX by enhanced activity of GGH. 
{Galivan et al, 1987). {Figure 3.5). 
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Figure 3.5. The action of methotrexate (MTX) and three major resistance 
mechanisms to MTX. MTX enters the cell mainly by means of reduced 
folate carrier (RFC)� .Once into the cell, MTX undergoes polyglutamation 
by the action of the enzyme, folypolyglutamate synthetase (FPGS)� . 
Poiyglutamated form of MTX is a potent inhibitor of dihydrofolate 
reductase (DHFR)� that is critical for DNA synthesis. Any defects of these 
important enzymes involved in MTX metabolism can contribute to MTX 
resistance in tumor cells, 
(modified from Bertino et al, 1996) 
3.1.2.3 5-Fluorouracil (5-Fu) 
5-fluorouracil (5-Fu) is a fluorinated pyrimidine analog that has been widely 
used alone or in combination for treatment of various neoplastic diseases, especially 
cancers of breast and digestive organs. The chemical structure of 5-Fu was shown in 
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Figure 3.6. In fact, 5-Fu itself is not cytotoxic, the anticancer activity and its 
cytotoxicity are mainly come from its anabolites. 
5 
f^ l H Figure 3.6. The chemical structure of 5-fluorouracil (5-Fu). 
H 
Once 5-Fu enters the cells by means of the facilitated transport mechanism as 
uracil, it can be converted into several active metabolites intracellularly, including 
fluorodeoxyuridine monophosphate (FdUMP), flurodeoxyuridine triphosphate 
(FdUTP) and fluorouridine triphosphate (FUTP) by a series of enzymatic catalysis. 
{Wohlhueter et al, 1980). Furthermore, by the action of the enzyme --- thymidine 
phosphorylase (TP), it can reversibly convert 5-Fu into fluorodeoxyuridine (FUDR) 
that can then be converted into the active metabolite FdUMR These active 5-Fu 
metabolites can disrupt DNA synthesis and RNA normal function by inhibiting the 
activity of the enzyme thymidylate synthase (TS) and misincorporation into DNA and 
RNA. {Daher et al, 1990). 
For 5-Fu inactivation, it can be catabolized to dihydrofluorouracil (DHFU) by 
the enzyme --- dihydropyrimidine dehydrogenase (DPD) that is a rate-limiting 
enzyme catalyzing the reduction of uracil to 5,6-dihydrouracil. (Diasio and Harris, 
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1989). Due to the abundantly expression of DPD in liver, the majority of the 
administered 5-Fu catabolism occurs mainly in the liver. The schematical description 
of 5-Fu metabolism was shown in Figure 3,7. 
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Figure 3.7, The metabolism of 5-fluorouracil (5-Fu). 5-Fu can be converted in to three 
major active metabolites, including fluorodeoxyuridine monophosphate 
(FdUMP), flurodeoxyuridine triphosphate (FdUTP) and fluorouridine 
triphosphate (FUTP) through a series of enzymatic reaction. By the action of 
thymidine phosphorylase (TP), it can reversibly convert 5-Fu into 
fluorodeoxyuridine (FUDR) that can then convert into FdUMR These 5-Fu 
metabolites can result in thymidylate synthase (TS) inhibition and 
misincoporation into RNA so that it can cause DNA and RNA damage 
consequently. Whereas, for 5-Fu catabolism, it is mainly inactivated by 
dihydropyrimidine dehydrogenase (DPD) that can convert 5-Fu into 
dihydrofluorouracil (DHFU). 
(modified from Daniel et al, 2003) 
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As mention before, TS is inhibited by the active metabolites of 5-Fu. Normally, 
TS catalyzes the reductive methylation of deoxyurdine monophosphate (FUMP) to 
deoxythymidine monophosphate (FdTMP) accompanied with the reduced folate 
5,10-methylenetetrahydrofolate (CH2THF) as the methyl donor. This reaction is very 
critical because it can provide the sole de novo source of thymidylate that is essential 
for DNA synthesis. Although the exact molecular mechanism about the TS inhibition 
is not fully known, one proposed model is shown in Figure 3.8. It indicates that TS is 
a 36kDa dimer protein. Each subunit consists of a nucleotide-binding site and a 
binding site for CH2THF. The 5-Fu metabolite — FdUMP binds to the 
nucleotide-binding site of TS and then forms a stable ternary complex. As a result, it 
blocks the binding of the original substrate — dUMP to TS so that it prevents dTMP 
biosynthesis finally. (Santi et al, 1974). Depletion of dTMP can raise a lot of 
profound problems on cellular metabolism and viability. Firstly, decreased level of 
dTMP can result in subsequent depletion of deoxypyrimidine triphosphate (dTTP) so 
that it will disturb the cellular levels of the other deoxynucleotides (dATP, dCTP and 
dGTP) by various feedback mechanisms. {Jackson and Grindley, 1984). In addition, 
this imbalance of deoxynucleotides pool can block DNA synthesis and repair, 
resulting in lethal DNA damage eventually. {Houghton et al, 1995). Secondly, 
inhibition of TS can lead to accumulation of dUMP so that it will subsequently 
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increase the level of dUTR Thus, dUTP and FdUTP can be misincorporated into DNA 
and cause DNA damage seriously. {Mitrovski et al, 1994). Thirdly, in the presence of 
the high ratio of dUTP/dTTP, the repair of uracil and 5-Fu-containing DNA by the 
nucleotide excision repair enzyme …uracil-DNA-glycosylase (UDG) will become 
ineffective. (Lindahl, 1974). Therefore, it leads to impaired DNA repair and cell death 
finally. 
However, the DNA damage induced by misincorporation of dUTP can be 
alleviated by the enzyme --- pyrophosphatase dUTPase that can limit the intracellular 
amount of dUTP in cells. (Ladner，2001). Furthermore, thymidylate can also be 
salvaged from thymidine by means of the catalytic reaction by thymidine kinase (TK) 
in order to against TS inhibition. Evidence has also indicated that this salvage 
pathway might be one of the potential resistance mechanism of 5-Fu. (Grem and 
Fischer, 1989). 
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Figure 3.8. The proposed model about the mechanism of thymidylate synthase (TS) 
inhibition by 5-fluorouracil (5-Fu). The active metabolite of 5-Fu ---
FdUMP binds to the nucleotide-binding site and forms a stable ternary 
complex with TS so that it blocks the binding of the normal substrate ---
dUMP to the nucleotide-binding site. Thus, the dTMP synthesis is inhibited. 
Depletion of dTMP can lead to dNTPs pool imbalance and the enhanced 
levels of dUTP can cause DNA damage consequently. The extent of DNA 
damage caused by dUTP can be alleviated by the pyrophosphatase dUTPase 
and uracil-DNA glycosylase (UDG) that can limit the intracellular 
accumulation of dUTP and promote DNA repair respectively. Whereas, from 
the salvage pathway, thydiylate can also be salvaged by the action of 
thymidine kinase (TK). 
(modified from Daniel et al, 2003) 
Recently, researches pointed out that there are a few of biochemical response 
determinants that can be helpful for identification of 5-Fu sensitivity on cancer 
therapy. If these response determinants can be measured before 5-Fu treatment, 
patients who are unlikely to respond to 5-Fu can have opportunity to be treated with 
another cancer therapy as early as possible. These response determinants play 
important roles in 5-Fu metabolism, they are thymidylate synthase (TS), 
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dihydropyrimidine dehydrogenase (DPD) and thymidine phosphorylase (TP). For TS 
and TP, several evidences showed that their expressions in the tumors were related to 
the sensitivity of 5-Fu-based chemotherapy both in the laboratory and clinically. {Beck 
et al, 1994; Peters et al, 1994). And for DPD, previous studies also indicated that 
DPD levels showed inversely associated with the 5-Fu response. These findings 
suggested that 5-Fu is more likely to be effective when DPD activity is low. {Etienne 
et al, 1995). Moreover, by using the combination of more than one independent 
response determinants is more accurate to achieve a better 5-Fu response prediction 
than with just one determinant. For instance, tumors with both low TS and TP levels 
had a higher response rate than tumors with only one or the other gene expression is 
low. {Metzger et al, 1998). Tumors with high TS and DPD mRNA levels tend to be 
relatively highly resistance to 5-Fu so that it proves that there is a significant inverse 
correlations between sensitivity of 5-Fu and TS and DPD mRNA levels. (Ishikawa et 
al, 2000). 
3.1.2.4 Vincristine (VCR) and Taxol 
Vincristine (VCR) and taxol are the most promising new anti-cancer agents for 
cancer therapy in recent years. {Suffness and Wall, 1995). They all belong to 
microtubule inhibitors that can inhibit cell proliferation by acting on the rapid 
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polymerization dynamics of microtubules that are crucial for correct spindle function. 
The chemical structures of vincristine and taxol are shown in Figure 3,9. 
(a) Vincristine (VCR) (b) Taxol 
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Figure 3.9 (a) & (b). The chemical structures of vincristine (VCR) and taxol. 
(a) refers to vincristine; (b) refers to taxol. 
Microtubules are protein polymers that are key components of the cytoskeleton 
and involved in a diverse range of cellular functions, including mitosis and meiosis, 
motility, maintenance of cell shape and the intracellular trafflicking of 
macromolecules and organelles. {Desai and Mitchison, 1997; Oakley, 2000; Sharp et 
al, 2000). In fact, microtubules are hollow cylindrical tubes that are formed primarily 
by self-polymerization of a-tubulin and p-tubulin heterodimers into polymers. 
{Downing and Nogales, 1998; Nogales, 2000). The tubulin heterodimers are 
associated in a head-to-tail fashion to generate protofilaments which will associate in 
a lateral manner to form the hollow microtubules. {Figure 3.10). It is crucial to note 
that microtubules are not existed in a simple equilibrium. Oppositely, they show a 
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rapid and complex polymerization dynamics that requires energy come from the 
hydrolysis of GTP instead. {Wordeman andMitchison, 1994). 
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Figure 3.10. The process of the depolymerization of microtubules, a- and 
p-tubulin heterodimers first assemble to form a short microtubule 
nucleus. After that, the polymerization of microtubules occurs at both 
ends to form a cylinder that consists of tubulin heterodimers arranged 
in a head-to-tail protofiiaments fashion, 
(from Jordan and Wilson, 2004) 
Although vincristine and taxol are microtubule-targeting drugs, the mechanisms 
of their action on microtubules are completely different and it is shown in Figure 3,11. 
Vincristine is Vinca alkaloids that are extracted from the Madagascar periwinkle plant 
{Catharanthus roseus). Tubulin and microtubules are the major targets of vincristine. 
(Jordon et al, 1991). Vincristine serves as a "microtubule-destabilizing" agent that 
can depolymerize the microtubules and then inhibit microtubule polymerization at 
high concentration of vincristine. Therefore, the dividing cells were trapped in mitosis 
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and apoptosis will be triggered afterwards. (Jordon, 2002). 
For taxol, it belongs to the highly complex organic compound that is found from 
bark of Pacific yew tree Taxus brevifolia in 1967 by MC Wani and Monroe Wall. 
Unlike vincristine, taxol acts as a "microtubule-stabilizing" agent. Taxol can stabilize 
the microtubules and then enhance the polymerization of microtubules consequently. 
As a result, the suppression of the spindle-microtubule dynamics inhibits the dividing 
cells progressing from metaphase into anaphase so that the cells will be killed by 
apoptosis finally. (Kelling et al, 2003). 
Vincristine 
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Figure 3.11. The different mechanisms of the anti-mitotic actions on microtubules of 
vincristine (VCR) and taxol respectively. The left one refers to vincristine 
(in green-color) that acts as a "microtubule-destabilizing" agent which binds 
to the plus (+) end of the microtubule to suppress the microtubule dynamics. 
The right one refers to taxol (in red-color) that serves as a 
"microtubule-stabilizing" agent which binds to the interior surface of the 
microtubule instead to suppress its dynamics. The outcomes of these two 
microtubule inhibitors are also inhibit the proliferation of tumor cells and 
then trigger apoptosis finally, 
(modified from Jordon and Wilson, 2004) 
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3.1.2.5 Cisplatin (cis-DDP) 
cis-Diamminedchloroplatinum (II) (cisplatin) is an inorganic, square planner 
Pt(II) heavy metal complex that consisting of a central atom of platinum and 
surrounded by two chloride atoms and two ammonia molecules oriented in a cis 
configuration. The chemical structure of cisplatin was shown in Figure 3,12. And it is 
a widely used anticancer drug in the treatment of testicular, ovarian, bladder, germ 
cell, head and neck and small cell lung cancers. (Loehrer and Einhorn, 1984). 
H3N CI 
Figure 3.12. The chemical structure of cisplatin. 
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Cisplatin acts as a DNA damaging agent. So, DNA is the major cellular target for 
cisplatin. Inter- and intra-strand cross-linkages of DNA have been observed in the 
cisplatin cytotoxicity. {Eastman, 1991). {Figure 3,13). Furthermore, cisplatin can also 
react with the N-7 position of purines of DNA and form some mono-functional or 
bi-functional DNA adducts. Then, the DNA molecules in tumor cells are unwound 
and the cells then undergo cell death eventually. Thus, cells that have impaired DNA 
repair function are highly sensitive to cisplatin. But, the exact mechanism of the 
induction of apoptosis by the DNA adducts is still not fully understood. {Minn et al, 
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1995; Simonian et al” 1997). 
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Figure 3.13. The action of cisplatin on DNA molecules. Cisplatin is a DNA 
damaging agent that can inter- or intra-strand crosslink with DNA 
and then generate non-functional DNA adducts. These DNA 
adducts trigger cell death consequently, 
(from http://www. eloxatin. com/hcp. about4. asp) 
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3.2 Objectives 
The inter-relationship between the differential cellular responses to EGF and the 
alteration of the EGFR signaling between A431 parent cells and EGF-conditioned 
cells has been studied previously. According to a lot of reports, it demonstrated that 
the combination therapy by using the common anti-cancer drugs or agents with the 
EGFR-targeted strategies can greatly enhance the effectiveness of the regression of 
tumor cells. Based on these results, it can be proposed that in addition to the influence 
on EGF growth responses, EGF-conditioning might also modulate the sensitivity of 
cells to anti-cancer drugs. Therefore, the responses of A431 parent cells and 
EGF-conditioned cells to a number of common anti-cancer drugs/agent were studied 
in this chapter. 
After that, the underlying mechanisms contributed to the differential drug 
sensitivity in A431 parent cells and EGF-conditioned cells were investigated by first 
studying the expression levels of their cellular specific targets and then the process of 
drug-induced apoptosis. 
Alteration of EGFR signaling by EGF-conditioning may be responsible for the 
observed anti-cancer drugs sensitivity patterns in tumor cells. Besides, combinations 
of EGFR signaling modifiers with anti-cancer drugs were also performed so as to 
understand more information about this inter-relationship. It may provide new 
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insights for the development of new approaches through perturbation of signal 
transduction pathway instead of conventional cancer therapies. 
I l l 
3.3 Materials and Methods 
3.3.1 Materials 
Chemical Company 
> 1 -bromo-3-chloropropane (BCP) Molecular Research Centre 
> 2X trypsin with EDTA Gibco / Life Technologies Ltd. 
> 3-[4,5 -Dimethtlthiazol-2-yl] -2,5 -diphenyl-tetrazolium 
Sigma 
bromide (MTT) 
> 5-fluorouracil Sigma 
> Acrylamide / Biacrylamide BIO-RAD 
> Agarose Invitrogen Corporation. 
> Ammonium persulphate Sigma 
> Apigenin Calbiochem 
> Aprotinin Boehringer Mannheim 
> BCA protein assay reagents Boehringer Mannheim 
> Benchmark prestained protein marker Invitrogen Corporation 
> Boric acid USB 
> Bromophenol blue Sigma 
> Butanol BDH Laboratory Suppliers 
> Camptothecin Calbiochem 
> Chloroform BDH Laboratory Supplies 
> Cisplatin Sigma 
> Citric acid USB 
> Copper (II) Sulphate* 5H2O Sigma 
> Diethyl pyrocarbonate (DEPC) USB 
> Dimethyl sulfoxide (DMSO) Sigma 
> Dulbecco's modified eagles's medium (DMEM) Gibco / Life Technologies, Ltd. 
> ECL Western blotting detection reagents Amersham Biosciences 
> EGF Prepotect 
> Ethanol BDH Laboratory Suppliers 
> Ethidium bromide Sigma 
> Ethylenediaminetetraacetic acid (EDTA) USB 
> Fetal bovine serum Gibco / Life Technologies, Ltd. 
> Formaldehyde Sigma 
> Gene specific primers Gibco / Life Technologies, Ltd. 
> Isoamyl alcohol Sigma 
> Isopropanol BDH Laboratory Suppliers 
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> Leupectin Boehringer Mannheim 
> L-glutamate Gibco / Life Technologies, Ltd. 
> Methanol BDH Laboratory Suppliers 
> Methotrexate Sigma 
> N,N,N, -tetramethylethylenediamine (TEMED) BIO-RAD 
> Nylon membrane Amersham Biosciences 
> Oligo-dT primer Gibco / Life Technologies, Ltd. 
> PD98059 Calbiochem 
> Phenol USB 
> Phenylmethysulfonylfluorid (PMSF) Boehringer Mannheim 
> Phosphate Buffer Saline (PBS) Gibco / Life Technologies, Ltd. 
> Polyoxyethylenesorbitan monolaurate (Tween 20) USB 
> Proteinase K Sigma 
> Rapid-hyb Buffer Amersham Biosciences 
> Rediprime ™ DNA Labeling System Amersham Biosciences 
> Reverse Transcriptase Gibco / Life Technologies, Ltd. 
> RNase A Sigma 
> Sodium acetate Sigma 
> Sodium chloride USB 
> Sodium dodecyl sulfate (SDS) Gibco / Life Technologies, Ltd. 
> Sodium ortho vanadate Sigma 
> Taxol Sigma 
> Thimersol Sigma 
> TRI-Reagent Molecular Research Centre 
> Tris-base USB 
> Tris-HCl Gibco / Life Technologies, Ltd. 
> Triton X-100 Boehringer Mannheim 
> Tyrophostin A25 Calbiochem 
> Vincristine Sigma 
Culture Wares Company 
> 60mm and 100 mm culture dishes Coming / Falcon 
> 75cm^ culture flask Coming / Falcon 
> 96-well flat-bottom culture plate Coming / Falcon 
> Microfuge tubes MBP 
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Instrument Company 
> Film cassette Kodak 
> Hybridization Owen Robbins Scientific Model 1000 
> Immobilon-P transfer membrane Millipore 
> Microplate Reader Molecular Device 
> Mini-PROTEAN® II Electrophoresis Apparatus BIO-RAD 
> Thermal Cycler 9700 Perkin Elmer 
> Thick Blotter Papers BIO-RAD 
> Trans-Blot® SD Semi-transfer cell BIO-RAD 
> UV crosslinker UVP 
> UV transilluminator UVP 
> X-rays film Kodak / Fuji 
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3.3.2 Methods 
3.3.2.1 Cell Lines 
As mention in the previous chapter, the human squamous A431 parent cells and 
its subline --- EGF-conditioned cells that is established by chronic exposure to EGF 
were cultured in Dulbecco modified Eagle's medium supplemented with 10% fetal 
bovine serum and 5mM L-glutamate in the 37^C humidified 10% CO2 incubator. 
3.3.2.2 Determination of Drug Sensitivity by MTT Assay 
The sensitivity to various anti-cancer drugs / agents between A431 parent cells 
2 
and EGF-conditioned cells were determined by MTT Assay. A431 parent cells (6x10 ) 
and EGF-conditioned cells (12x10') were first seeded in the 96-well plates for 2 days 
in order to reach the exponential phase of the cells. After 2 days, the anti-cancer 
drugs/agents would be added into the 96-well plates and the cells were then incubated 
in the 37^C incubator for further 3 days. Then, MTT assay was performed. The details 
have been described in Section 2.3.2.3. 
3.3.2,2,1 Determination the Influence of EGFR Signaling Modifiers on the 
Differential Anticancer Drugs Sensitivity by MTT Assay 
The influence of various signaling modifiers that targeting different parts of 
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EGFR signaling on the differential drugs sensitivity was investigated by MTT assay. 
As mention in Section 3.3.2.2, A431 parent cells (6x1 O】）and EGF-conditioned cells 
(12x10 ) were first seeded in the 96-well plates for 2 days in order to reach the 
exponential phase of the cells. After 2 days, EGFR signaling modifiers and 
anti-cancer drugs/agents would be added into the 96-well plates at the same time and 
the cells were then incubated in the 37V incubator for further 3 days. Then, MTT 
assay was performed. The details have been described in Section 2.3.2.3. 
3.3.2.3 Semi-Quantitative RT-PCR 
The mRNA expression levels of genes involved in the differential drug 
sensitivity in A431 parent cells and EGF-conditioned cells were investigated by 
Semi-Quantitative RT-PCR. 
3J.2JJ Preparation of RNA Samples 
A431 parent cells (4x10^) and EGF-conditioned cells (5x10^) were grown until 
about 70-80% confluence in 100mm culture dish. Then, medium was removed and 
cells were lysed with 1ml TRI-Reagent. The lysates were then collected into a 1.5ml 
microfuge. Next, 0.1ml BCP (1 -bromo-3-chloropropane) was added and the mixture 
was shaken vigorously in order to extract out protein contaminant from the RNA. 
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Then, the mixture was stayed at room temperature for 15 minutes. After centrifugation 
at HOOOrpm at for 10 minutes, the soluble RNA was collected and extracted in 
the upper aqueous supernatant. After that, 0.5ml isopropanol was added followed with 
vigorously shaking and stored at room temperature for 10 minutes to allow the 
precipitation of RNA. Next, the supernatant was transferred to a new microfuge tube 
and the RNA pellet was obtained by centrifugation at 14000rpm for 15 minutes at 
To further wash and precipitate the RNA, 1ml 75% ethanol was added and the sample 
was centrifuged at MOOOrpm at for 8 minutes. The upper aqueous supernatant 
was then removed and the RNA pellet was air-dried at room temperature for 
15minutes until the pellet became semi-white. Finally, the RNA pellet was dissolved 
in 20|li1 DEPC-H2O and incubated at 55-60^C for 10 minutes. Thus, the concentration 
of RNA was calculated by measurement of OD260 and OD280 afterwards and the 
RNA samples were then be stored at -80^C for later use. 
3.3,2.3,2 RT-PCR 
First of all, 2.5)ag RNA samples from A431 parent cells and EGF-conditioned 
cells were prepared and undergone reverse transcription (RT) by employing oligo dT 
primer, dNTP mix (lOmM) and Superscript RNase H-reverse transcriptase. After that, 
the RT-transcribed cDNAs from each sample were further amplified by polymerase 
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chain reaction (PGR) with different desired primers under proper condition. The 
amplification process was carried out in the thermal cycler 9700. The desired primers 
for different cellular targets, including dihydrofolate reductase (DHFR), reduced 
folate carrier (RFC), dihydropyrimidine dehydrogenase (DPD), thymidine 
phosphorylase (TP), and the related condition were mentioned in the result part. 
After PGR, the products were resolved in the 1% (w/v) agarose gel stained with 
0.5mg/ml ethidium bromide (EtBr) by electrophoresis. Finally, the expression levels 
of desired molecules were visualized under the UV-tranilluminator. 
3.3.2.4 DNA Fragmentation Assay 
The drug-induced apoptosis in cancer cells could be determined by DNA 
fragmentation assay (DNA ladder experiment). If there is any occurrence of apoptosis， 
a series of DNA ladder could be detected. A431 parent cells (1x10^) and 
EGF-conditioned cells (2x10^) were first seeded in 60mm culture dishes for 2 days to 
reach the exponential phase. Then, medium was removed and replaced by the addition 
of different concentration of various anti-cancer drugs (including, camptothecin, 
methotrexate, 5-fluorouracil, vincristine or taxol) for further 3 days. After that, cells 
were washed by 2ml IX PBS and harvested by trypsinization with 1ml 2X trypsin. All 
used media were collected in a snap cap. Cells were then lysed in 0.5ml lysis buffer 
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(including 5mM Tris-HCl, lOOmM EDTA, 1% SDS, 0.4|Lig/ml Proteinase K and 
distilled water) and incubated at 37^C overnight or 45^C for 3-4 hours. Subsequently, 
DNA was extracted with 0.5ml buffer-saturated phenol and 0.5ml chloroformlisoamyl 
alcohol (24:1) respectively and then vortex vigorously and centrifuged at HOOOrpm 
for 2 minutes in order to remove those protein contaminants from the DNA. The 
upper aquaeous layer was then transferred into a new 1.5ml microfiige tube and the 
DNA was further extracted in 1ml chloroformrisoamyl alcohol (24:1). After that, 
DNA was participated in 50|li1 3M sodium acetate (NaOAc) and 1ml 100% ice-colded 
absolute ethanol at -20^C overnight. 
Next day, DNA pellet was obtained by centrifugation at 14000 rpm for 35 
minutes. The supernatant was removed and air-dried. Then, the DNA pellet was 
dissolved in 0.4mg/ml RNase A in TE buffer (lOmM Tris-HCl and O.SmM EDTA, pH 
8.0) for digestion at 37^C over 2 hours. 
Then, the concentration of DNA from each sample was quantified by measuring 
the absorbance at 260nm and 280nm. 30|Lig DNA from each samples were prepared 
and loaded into 1.5% (w/v) agarose gel stained with 0.5mg/ml ethidium bromide 
(EtBr) in IX TBE buffer (including 0.089M Tris base, 0.089M boric acid and 2mM 
EDTA, pH. 8.0). Thus, the DNA ladder was separated by electrophoresis and 
visualized under the UV transilluminlator afterwards. 
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3.3.2.5 Western Blot Analysis 
The protein expression levels of topoisomerase I (Topo I) were detected by 
Western blot analysis. The details have been mentioned in Section 2.3.2.4. 
3.3.2.6 Northern Blot Analysis 
The mRNA expression level of thymidylate synthase (TS) in A431 parent cells 
and EGF-conditioned cells was detected by Northern Blot Analysis also. First of all, 
the total RNAs of A431 parent cells and EGF-conditioned cells were prepared as 
mentioned in Section 3.3.2.3.1. Then, 7jig of total RNAs were collected and run in 
1% denaturing formaldehyde agarose gel After that, the RNAs were transferred onto 
the nylon membrane overnight. Next day, the membranes were cross-linked by UV 
light and ready for further hybridization. 
The purified cDNA probes were hybridized and labeled with [^^P]-dCTP by 
employing the Rediprime™ Random prime labeling system. First, the membranes 
were equilibrated in 2X Nucleic acid transfer buffer (SSC) (including sodium chloride 
and citric acid) and pre-hybridized with 10ml hybridization buffer at 65^C for 10-15 
minutes in the hybridization oven. On the other hand, the cDNA probes were first 
diluted to about 20-25 ng with TE buffer in 45)li1 and then denatured by boiling for 5 
minutes and kept on ice for further 5 minutes. After that, the probes were labeled with 
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5ml [ P]-dCTP by Rediprime Random prime labeling system. The mixtures were 
incubated at 37^C for 10 minutes and 5|il 0.2M EDTA was added in order to stop the 
labeling reaction. The radio-labeled probes were then denatured by boiling for 5 
minutes and kept on ice for 5 minutes. So, the radio-labeled cDNA probes could be 
mixed with the hybridization buffer and hybridized with the pre-hybridized 
membranes at 65^C for 2 hours in the hybridization oven. 2 hours later, the 
membranes were washed with SDS-containing SSC solution at 65^C for 20 minutes 
once and 15 minutes twice in the hybridization oven. After washing those 
non-specific labeling on the membranes, the expression pattern of mRNA was then 




3.4.1 The Responses to Various Anti-cancer Drugs / Agents in A431 
Parent Cells and EGF-conditioned Cells 
The dose response curves to a series of different anti-cancer drugs and agents in 
A431 parent cells and EGF-conditioned cells were measured by MTT assay and 
shown in Figure 3.14. Seven anti-cancer drugs and agent were employed in the 
present study. They included camptothecin (CPT), methotrexate (MTX), 
5-fluorouracil (5-Fu), vincristine (VCR), taxol, cisplatin (cis-DDP) and y-radiation. As 
shown in Figure 3.14, differential sensitivity to different anti-cancer drugs or agent 
was found between A431 parent cells and EGF-conditioned cell. It was summarized 
in Table 3,1. 
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(a) Camptothecin (CPT) (b) Methotrexate (MTX) 
Camptothecin (CPT) Methotrexate (MTX) 
1 2 0 — ^ ‘ —.一- 1 2 0 「 1 ' - " " — ― ― — = — ： — — — • — -
W ^ ^ 1 � �• ' ^ s . ‘ 
,：：、义 
0 ~•—‘ 1 1 1 y 0 ‘ ‘ ‘ X T 
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Concentration (^M) Concentration (ng/ml) 
(d) Vincristine (VCR) 
(c) 5-fluorouracil (5-Fu) 
5-Fluorouracil (5-Fu) Vincristine (VCR) 
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Figure 3.14 (a)-(g). The sensitivity to various anti-cancer drugs and agent in A431 parent 
cells and EGF-conditioned cells as measured by MTT assay. The error 
bar is standard derivation from more than three sets of different 
experiments. AP (the blue line) refers to A431 parent cells and AC (the 
pink line) refers to EGF-conditioned cells. 
Anti-cancer drugs/agent Drug sensitivity 
O Camptothecin (CAM) AP>AC  
e Methotrexate (MTX) AP>AC  
珍 S-fluorouracil (5-Fu) AP<AC  
O Vincristine (VCR) AP > AC — 
e Taxol A P � A C 
O Cisplatin (cis-DDP) AP �A C — 
O Ionizing radiation AP �A C 
Table 3.1. The summary of differential sensitivity to various anti-cancer 
drugs/agent between A431 parent cells and EGF-conditioned cells. 
“>，，refers to higher sensitivity; “<‘‘ refers to lower sensitivity; 
“ � “ refers to similar sensitivity. AP refers to A431 parent cells and AC 
refers to EGF-conditioned cells. 
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According to Table 3.1, differential responses to various anti-cancer drugs/agent 
between A431 parent cells and EGF-conditioned cells were observed. Compared with 
A431 parent cells, it showed that EGF-conditioned cells had a lower sensitivity to the 
majority of anti-cancer drugs, including camptothecin, methotrexate, vincristine and 
taxol. However, 5-fluorouracil was an exceptional case. EGF-conditioned cell had a 
greater sensitivity to 5-fluorouracil than A431 parent cells contrarily. And for cisplatin 
and ionizing radiation，the sensitivity seemed to be similar between two cell lines. As 
a result, it indicated that EGF-conditioning not only alters the cellular responses to 
EGF, but also changes the sensitivity of A431 cells to different anti-cancer drugs. 
Based on the previous study, the differential sensitivity of EGF-conditioned cells to 
various anti-cancer drugs might be due to the alteration of EGFR signaling also. 
Further investigation should be needed in this aspect in the future. But, first of all, 
those anti-cancer drugs demonstrated the differential sensitivity in A431 parent cells 
and EGF-conditioned cells were chosen for further investigation, in particular, the 
relationship between the differential drug sensitivity pattern and the expressions of the 
classical cellular drug resistant molecules in two cell lines. 
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3.4.2 The Expressions of Classical Cellular Drug Resistant Factors in 
EGF-conditioning-associated Differential Anti-cancer Drugs 
Sensitivity 
As mentioned in the previous section, differential sensitivity to various 
anti-cancer drugs was found between A431 parent cells and EGF-conditioned cells. 
EGF-conditioned cells were more resistant to camptothecin, methotrexate, vincristine 
and taxol, but more sensitive to 5-fluorouraciL The underlying mechanism contributed 
to the differential sensitivity to camptothecin, methotrexate, 5-fluorouracil, vincristine 
and taxol were therefore chosen for further investigation. First of all, the investigation 
was started by studying the role of the classical cellular drug resistant molecules and 
also drug-induced apoptosis on EGF-conditioning related drug sensitivity in cells. 
3.4.2.1 Camptothecin Sensitivity 
As shown in Figure 3,14 (a}, EGF-conditioned cells were relatively more 
resistant to camptothecin treatment than A431 parent cells. The expression level of its 
major cellular target, topoisomerase I (Topo I), and the occurrence of apoptosis were 
studied by Western Blot analysis and DNA fragmentation assay respectively. 
. As described before, the anti-tumor activity of camptothecin is mainly dependent 
on its inhibition of topoisomerase I that is an important enzyme involved in DNA 
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replication in cells. Furthermore, the camptothecin sensitivity was believed to be 
related to topoisomerase I concentration in tumor cell lines. {Sugimoto et al, 1990), 
i.e., the higher expression level of topoisomerase I, the higher sensitivity to 
camptothecin. The expression level of topoisomerase I in A431 cells was shown in 
Figure 3.15 and it indicated that A431 parent cells had a higher level of 
topoisomerase I than that in EGF-conditioned cell. Therefore, the resistance to 
camptothecin in EGF-conditioned cells might be due to the decreased level of 
topoismoerase I. 
The camptothecin-induced apoptosis in A431 parent cells and EGF-conditioned 
cells were detected by DNA fragmentation assay. As shown in Figure 3.16，it showed 
that camptothecin induced apoptosis in both two cell lines and the amplitudes of the 
DNA fragmentation seemed to be similar. Hence, the differential sensitivity to 
camptothecin between A431 parent cells and EGF-conditioned cells might not be due 
to the camptothecin-induced apoptosis at all. To confirm such correlation, further 
experiment should be performed, such as using the antisense transfection of 
topoisomerase I oligonucleotide. 
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Figure 3.15 (a)-(b). The expression levels of topoisomerase I in A431 parent cells and 
EGF-conditioned cells as detected by Western Blot analysis, p-actin 
was used as the internal standard in order to ensure the equal amount 
of sample loading. AP refers to A431 parent cells and AC refers to 
EGF-conditioned cells. The experiments have been repeated twice and 
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Figure 3.16. The camptothecin-mduced apoptosis in A431 parent cells and 
EGF-conditioned ceils as detected by DNA fragmentation assay. 
The treatment of camptothecin was 48 hours. The experiments have 
been repeated twice and results from both experiments were similar. 
The one shown is the most representative one. AP refers to A431 
parent cells and AC refers to EGF-conditioned cells. 
M : The lOObp DNA ladder marker 
C : Control 
0.01 : 0.001 i^ M camptothecin 
0.02 : 0.002 |LIM camptothecin 
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3.4.2.2 Methotrexate Sensitivty 
From Figure 3.14 (b), it showed that EGF-conditioned cells were more resistant 
to methotrexate than A431 parent cells. As stated previously, the two common 
mechanisms contributed to methotrexate resistance are the amplification of its major 
cellular target，dihydrofolate reductase (DHFR), and the impaired transport by 
reduced folate carrier (RFC) of MTX in tumor cells. {Allegra, 1990; Schweitzer, et al, 
1990). So, the mRNA expression levels of dihydrofolate reductase and reduced folate 
carrier in A431 parent cells and EGF-conditioned cells were compared by 
semi-quantitative RT-PCR respectively. 
As mention before, methotrexate can competitively inhibit the activity of 
dihydrofolate reductase that is essential for the maintenance of intracellular folate 
pools in cells. Therefore, methotrexate resistance would be expected to be associated 
with increased level of dihydrofolate reductase. As shown in Figure 3.17 (a), the 
expression level of dihydrofolate reductase in A431 parent cells and EGF-conditioned 
cells was shown to be similar. 
Besides, except dihydrofolate reductase, reduced folate carrier is also another 
critical determinant for investigation of methotrexate sensitivity. It is because reduced 
folate carrier is the most major route for the uptake of methotrexate. Thus, decreased 
mRNA expression level of reduced folate carrier has been observed in several in vitro 
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models of methotrexate-mediated resistance. {Moscow et al” 1997). The mRNA 
expression level of reduced folate carrier of A431 parent cells and EGF-conditioned 
cells were measured by semi-quantitative RT-PCR and shown in Figure 3.17 (c). 
From the results, it demonstrated that the level of the reduced folate carrier expression 
in two cell lines was almost similar. 
Hence, the methotrexate-mediated resistance in EGF-conditioned cells might not 
be related to these two cellular targets. 
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(a) Dihydrofolate reductase mUFm (b) P-actin (for DHFR) 
AP AC AP AC 
1 1.07 1 0.93 
fc) Reduced folate carrier (RFC) (d) ^actin (for RFC) 
AP AC AP AC 
1 0.94 1 1.02 
Primers for Dihydrofolate Reductase (DHFR): (309bp) 
> Forward : 5' - CAC CGC TCA GGA ATG AAT TGA GAT A - 3' 
> Reverse : 5, - GGG TGA TTC ATG GCT TCC TTA TAA AC A G - 3, 
Primers for Reduced Folate Carrier (RFC): (333bp) 
> Forward: 5 ' -CCA AGC GCA GCC TCT TCT TC A A C C - 3 ' 
> Reverse: 5 ’ 一 CCG TCT ACG ACG GAG GTG CGA CGA CC - 3 ’ 
Primers for P-actin: (233bp) 
> Forward: GCG GGA AAT CGT GCG TGA CAT T - 3 ' 
> Reverse: 5 ’ - GAT GGA GTT GAA GGT AGT TTC GTG - 3 ’ 
PGR Condition: 
For DHFR, For RFC, 
94®C for Imin 94^C for Imin 
61^C for Imin 28 cycles 62V for Imin 30 cycles 
70^C for Imin f 70V for Imin f 
Figure 3.17 (a)-(d). The mRNA expression levels of (a) Dihydrofolate Reductase (DHFR) 
and (c) Reduced Folate Carrier (RFC) in A431 parent cells and 
EGF-conditioned cells as compared by semi-quantitative RT-PCR. 
The primers used for PGR were shown as above. In (b) and (d), p-actin 
were used as the internal standard in order to ensure the equal amount of 
samples loading. The numbers beneath each band are the relative 
expression ratio of the mRNA in the EGF-conditioned cells in relation to 
that in A431 parent cells. The value is the averages of data obtained from 
two to three different sets of experiments. AP refers to A431 parent cells 
and AC refers to EGF-conditioned cells. 
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Thereafter, the apoptosis pattern induced by methotrexate in A431 parent cells 
and EGF-conditioned cells were performed by DNA fragmentation assay. As shown in 
Figure 3.18, it indicated that methotrexate induced apoptosis in both cell lines, but the 
effects in EGF-conditioned cells were more significant than that in A431 parent cells. 
As a result, it suggested that the differential sensitivity to methotrexate between A431 
parent cells and EGF-conditioned cells might be due to differences in their apoptotic 
pathway. But, further identification of critical molecules involved in apoptotic 
pathway should be performed in order to verify the importance of apoptosis pathway 
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Figure 3.18. The methotrexate-induced apoptosis in A431 parent cells and 
EGF-conditioned cells as detected by DNA fragmentation assay. The 
treatment of methotrexate was 48 hours. The experiments have been 
repeated twice and results from both experiments were similar. The one 
shown is the most representative one. AP refers to A431 parent cells and AC 
refers to EGF-conditioned cells. 
M : The 1 OObp DNA ladder marker 
C : Control 
0.001 : 0.001 |ag/ml methotrexate 
0.002 : 0.004 |ig/ml methotrexate 
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3.4.2.3 5-fluorouracil sensitivity 
According to Figure 3.14 (c), it showed that EGF-conditioned cells were more 
sensitive to 5-fluorouracil than A431 parent cells. As mentioned before, there are a 
number of enzymes played crucial roles in 5-fluorouracil metabolism. They include 
thymidylate synthase (TS), dihydropyrimidine dehydrogenase (DPD) and thymidine 
phosphorylase (TP). Any deficiency of these enzymes could contribute to 
5-fluorouracil resistance in tumor cells. In other words, tumor cells that had higher 
expression levels of thymidylate synthase, dihydropyrimidine dehydrogenase and 
thymidine phosphorylase were more resistant to 5-fluorouraciL So, in the present 
study, the mRNA expression levels of three determinants were examined by Northern 
blot analysis and semi-quantitative RT~PCR respectively. As shown in Figures 3.19 & 
3.20, it demonstrated that the expression levels of both thymidylate synthase, 
dihydropyrimidine dehydrogenase and thymidine phosphorylase were lower in 
EGF-conditioned cells as compared with A431 parent cells. As a result, it may explain 
why EGF-conditioned cells had a higher sensitivity to 5-fluorouracil than A431 parent 
cells. The differential sensitivity of 5-fluorouracil between A431 parent cells and 
EGF-conditioned cells correlated with thymidylate synthase, dihydropyrimidine 
dehydrogenase and thymidine phosphorylase expressions. Further investigation of the 
mechanism contributed to this differential drug sensitivity because of the 
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EGF-conditioning is needed by performing antisense transfection experiments of 
these enzyme determinants in both cell lines. 
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(a) Thymidylate Synthase (TS) 
IS AP AC 
(b) The 18S and 28S rRNA 
AP AC 
Figure 3.19. The mRNA levels of thymidylate synthase (TS) in A431 parent 
cells and EGF-conditioned cells as detected by Northern blot 
analysis. In (b), the 18S and 28S rRNA was used as the indicator in 
order to ensure the equal amount of the sample loading. The 
experiments have been repeated twice and results from both 
experiments were similar. The one shown is the most representative 
one. AP refers to A431 parent cells and AC refers to 
EGF-conditioned cells. 
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(a) Dihydropyrimidine Dehydrosenase (DPD) (b) 0-actin (for DPD) 
AP AC AP AC 
m m m m ^ m m m w K t ^ m m m i m m m m 
1 0.40 1 1.06 
(d) B-actin (for TP) 
(c) Thymidine Phosphorylase (TP) 
AP AC AP AC 
1 0.55 1 0.95 
Primers for Dihydropyrimidine Dehydrogenase (DPD): (158bp) 
> Forward : 5'- CCT TAG CAA GCT CCA TCT C C - 3 ' 
> Reverse : 5, — CTC CAT TGC CAT CGATAG G - 3’ 
Primers for Thymidine Phosphorylase (TP): (152bp) 
> Forward: 5’ - TGG CTC AGT CGG GAC AGC A G - 3 ' 
> Reverse: 5, - TCC GCT GAT CAT TGG CAC CT - 3, 
Primers for p-actin: (233bp) 
> Forward: 5,- GCG GGAAAT CGT GCG TGA CAT T 一 3, 
> Reverse: 5，- GAT GGA GTT GAA GGT AGT TTC GTG - 3, 
PGR Condition: 
For DPD and TR 
94^C for Imin 
58V for Imin i 30 cycles 
70^C for Imin 
Figure 3.20 (a)-(d). The mRNA expression levels of (a) Dihydropyrimidine Dehydrogenase 
(DPD) and (c) Thymidine Phosphorylase (TP) in A431 parent cells and 
EGF-conditioned cells as detected by semi-quantitative RT-PCR. The 
primers used for PGR were shown as above. In (b) and (d), p-actin were used 
as the internal standard in order to ensure the equal amount of sample loading. 
The numbers beneath each band are the relative expression ratio of the mRNA 
in the EGF-conditioned cells in relation to that in A431 parent cells. The value 
is the averages of data obtained from two to three different sets of 
experiments. AP refers to A431 parent cells and AC refers to EGF-conditioned 
cells. 
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Moreover, the 5-fluorouracil-induced apoptosis patterns in A431 parent cells and 
EGF-conditioned cells were also compared by DNA fragmentation assay. The results 
were shown in Figure 3.21. According to the experimental results, the incidence of 
apoptosis in EGF-conditioned cells was shown to be greater than that in A431 parent 
cells. Theoretically, the greater the occurrence of apoptosis, the higher the 
responsiveness of tumor cells to that anti-cancer drug was found. Based on this 
conception, since EGF-conditioned cells were more sensitive than A431 parent cells, 
it should have greater amplitude of the DNA ladder. Therefore, it seemed that the 
differential of 5-fluorouracil sensitivity in A431 parent cells and EGF-conditioned 
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Figure 3.21. The 5-fluorouracil-mduced apoptosis in A431 parent cells and 
EGF-conditioned ceils as detected by DNA fragmentation assay. 
The treatment of 5-fluorouracil was 48 hours. The experiments have 
been repeated twice and results from both experiments were similar. 
The one shown is the most representative one. AP refers to A431 
parent cells and AC refers to EGF-conditioned cells. 
M : The 100 bp DNA ladder marker 
C : Control 
0.005 : 0 .005 |LIM 5-fluorouracil 
0.015 : 0.015 i^ M 5-fluorouracil 
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3.4.2.4 Vincristine and Taxol Sensitivity 
As shown in Figure 3.14 (d) & 3.14 (e), EGF-conditioned cells were more 
resistant to both vincristine and taxol as compared with A431 parent cells. As stated 
previously, vincristine and taxol belong to anti-microtubule agents to inhibit cell 
proliferation in cancer cells. Thus, they do not have any specific cellular targets for 
the investigation of their differential sensitivity in A431 parent cells and 
EGF-conditioned cells. So, we only studied the drug-induced apoptosis in these two 
cell lines. The results were shown in Figure 3,22. From the experimental results, it 
showed that the effects of the drug-induced apoptosis by vincristine and taxol were 
nearly the same in A431 parent cells and EGF-conditioned cells. As a result, it 
indicated that the differential sensitivity to these two drugs in both cell lines were not 
correlated to their apoptotic pathways. 
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(a) Vincristine (VCR) 
AP AC 
人 A 
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Figure 3.22 (a) & (b). The apoptosis patterns induced by (a) Vincristine and (b) Taxol in 
A431 parent cells and EGF-conditioned cells as detected by DNA 
fragmentation assay. The treatments of both vincristine and taxol were 
48 hours. The experiments have been repeated twice and results from 
both experiments were similar. The one shown is the most representative 
one. AP refers to A431 parent cells and AC refers to EGF-conditioned 
cells. 
M : The 100 bp DNA ladder marker 
C : Control 
0.00075 : 0.00075 jig/ml Vincristine / Taxol 
0.0015 : 0.0015 |ag/ml Vincristine / Taxol 142 
3.4.3 EGFR Signaling Modifiers and Differential 
Anti-cancer Drugs Sensitivity by MTT Assay 
From some literature reviews, it is noted that the drug resistance mechanisms 
might have interaction with the growth factor signaling pathway in cells. {Davies and 
Chamberlin, 1996; Cvijic et al” 1998; Aigner et al, 2000), Therefore, 
EGF-conditioning might not only alter the signaling pathways, but also the drug 
sensitivity pattern in the cells. In order to study the interaction between the differential 
sensitivity pattern to anti-cancer drugs (including methotrexate, vincristine and taxol) 
and EGFR signaling, various signaling modifiers, particularly those involved in the 
Ras/Raf/MAPK pathway or / and the Jak/Stat pathway were combined with the 
desired drugs and the corresponding cellular responses were measured by MTT assay 
respectively. 
3.4.3.1 Methotrexate 
The influences of various EGFR signaling modifiers (particularly the 
Ras/Raf/MAPK pathway), including ZM336372 (Raf inhibitor), PD98059 (MEK 
inhibitor) and Apigenin (ERKs inhibitor) on the response to methotrexate of A431 
parent cells and EGF-conditioned cells were determined by MTT assay and shown in 
Figure 3,23. As shown in Figure 3,23 (a), the Raf inhibitor, ZM336372, seemed not 
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to affect the responses of A431 parent cells and EGF-conditioned cells to 
methotrexate. 
On the other hand, in the presence of the ERKs inhibitor, apigenin, it could 
clearly see that the cells became more resistant to methotrexate in both cell lines. In 
the case of the MEK inhibitor, PD98059, the modifier did not affect the responses of 
A431 parent cells to methotrexate but slightly increased the resistance in 
EGF-conditioned cells. As a result, alteration of EGFR signaling by EGF-conditioning 
might have close relationship with methotrexate-meidated resistance in tumor cells. 
But, additional investigation about the relationship between the alteration of EGFR 
signaling pathway and methotrexate resistance in EGF-conditioned cells is needed in 
the future. 
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(a) ZM336372 (Raf inhibitor) + Methotrexate 
AP AC 
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(b) PD98059 (MEK inhibitor) + Methotrexate 
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(c) Ayisenin (ERKs inhibitor) + Methotrexate 
AP AC 
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Figure 3.23 (a)-(c). The responses of A431 parent cells and EGF-conditioned cells to 
methotrexate (MTX) in combination with various EGFR 
signaling modifiers involved in the Ras/Raf/MAPK pathway, 
including (a) ZM336372 (Raf inhibitor); (b) PD98059 (MEK 
inhibitor); (c) Apigenin (ERKs inhibitor) by MTT assay. AP 
refers to A431 parent cells and AC refers to EGF-conditioned cells. 
The blue line represents the treatment with the corresponding 
signaling modifier; the pink line represents the treatment without 
the addition of modifier. The survival for treatment with 
combination of methotrexate (MTX) and EGFR modifiers had 
already been normalized by the toxicity of the modifiers used. The 
experiments have been repeated twice and results from both 




As shown in Figure 3.24 (a)-(b), in the presence of the modifiers in the 
Ras/Raf/MAPK pathway, L744832 (Ras inhibitor), or the Jak/Stat pathway, AG490 
(Jak2 inhibitor), the responses to vincristine between A431 parent cells and 
EGF-conditioned cells were shown to be nearly the same. Thus, it could indicate that 
the differential sensitivity to vincristine in two cell lines might not be related to the 
alteration of the EGFR signaling in the EGF-conditioned cells. 
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Figure 3.24 (a)-(b). The responses of A431 parent cells and EGF-conditioned cells to 
vincristine (VCR) in combination with various EGFR signaling 
modifiers involved in the Ras/Raf/MAPK pathway and the Jak/Stat 
pathway respectively, including (a) L744832 (Ras inhibitor); (b) 
AG490 (Jak2 inhibitor) by MTT assay. AP refers to A431 parent cells 
and AC refers to EGF-conditioned cells. The blue line represents the 
treatment with the corresponding signaling modifier and the pink line 
represents the treatment without the addition of modifier. The survival for 
treatment with combination of vincristine (VCR) and EGFR modifiers 
had already been normalized by the toxicity of the modifiers used. The 
experiments have been repeated twice and results from both experiments 
were similar. The one shown is the most representative one. 
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3.4.3.3 Taxol 
For taxol, the modifiers involved in both the Ras/Raf/MAPK and the Jak/Stat 
pathways, including L744832 (Ras inhibitor), Jaks inhibitor 1 (Jak inhibitor 1) and 
AG490 (Jak2 inhibitor) have been employed. As mention before, A431 parent cells 
had a higher sensitivity to taxol than EGF-conditioned cells. Moreover, A431 parent 
cells had higher expression levels of those signaling molecules involved in the 
Ras/Raf/MAPK pathway (except Ras) than that in EGF-conditioned cells. Therefore, 
in the presence of signaling modifiers that targeting the Ras/Raf/MAPK pathway, the 
cells become more sensitive. From Figure 3,25, after combination with the Ras 
inhibitor — L744832, the responsiveness to taxol of A431 parent cells and 
EGF-conditioned ceils were increased. Furthermore, the alteration of cellular 
responses seemed to be more significant in EGF-conditioned cells than that in A431 
parent cells. 
On the other hand, the expression levels of those signaling molecules involved in 
the Jak/Stat pathway were higher in EGF-conditioned cells rather than that in A431 
parent cells. So, after the addition of the modifiers targeting the Jak/Stat pathway, 
A431 cells were shown to be more sensitive. According to Figure 3.26 (a) & (b), for 
the modifiers in the Jak/Stat pathway, Jak inhibitor 1 and AG490, both of them 
seemed to have no significant effect on the differential responses of A431 parent cells 
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and EGF-conditioned cells. 
Consequently, it could suggest that the taxol-mediated resistance in 
EGF-conditioned cells might be correlated with the changes in its EGFR signaling. 
More experiments should be performed to further confirm in this aspect. 
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Figure 3.25. The responses of A431 parent cells and EGF-conditioned cells to taxol in 
combination with various EGFR signaling modifiers involved in the 
Ras/Raf/MAPK pathway, including L744832 (Ras inhibitor) by MTT 
assay. AP refers to A431 parent cells and AC refers to EGF-conditioned 
cells. The blue represents the treatment with the corresponding signaling 
modifier; the pink line represents the treatment without the addition of 
modifier. The survival for treatment with combination of taxol and EGFR 
modifiers had already been normalized by the toxicity of the modifiers 
used. The experiments have been repeated twice and results from both 
experiments were similar. The one shown is the most representative one. 
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Figure 3.26 (a) & (b). The responses of A431 parent cells and EGF-conditioned cells to 
taxol in combination with various EGFR signaling modifiers 
involved in the Jak/Stat pathway, including (a) Jak inhibitor 1 
(Jaks inhibitor); (b) AG490 (Jak2 inhibitor) by MTT assay. AP 
refers to A431 parent cells and AC refers to EGF-conditioned cells. 
The blue line represents the treatment with the corresponding 
signaling modifier; the pink line represents the treatment without the 
addition of modifier. The survival for treatment with combination of 
taxol and EGFR modifiers had already been normalized by the 
toxicity of the modifiers used. The experiments have been repeated 
twice and results from both experiments were similar. The one 
shown is the most representative one. 
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3.5 Discussion 
Currently, drug resistance is one of the major clinical obstacles in the treatment 
of human cancers. {Powis, 1994; Verwei and de Jonge, 2000). It is partly due to the 
inadequate understanding about the interaction of the underlying mechanisms and 
cellular behaviours of anti-cancer drugs with the pathogenesis of cancers. On the 
other hand, signal transduction plays critical roles in a lot of cellular processes, 
including cell proliferation, cell survival and apoptosis. It is a rather complicated 
network that consists of many cross-talks between different signaling pathways at 
different cellular levels and also many phosphorylation of protein kinase cascades. 
{Grammer and Blenis, 1997; Campbell et al, 1998). Any alteration of the components 
in the signaling pathways can contribute to the occurrence of cancer. Therefore, 
signaling pathways have a very close relationship with drug resistance mechanism 
indeed. For example, from several researches, it showed that protein kinase C (PKC) 
and protein kinase A (PKA) together with MAPK have been associated with 
over-expression of P-glycoprotein (PgP) that is a multi-drug resistance related protein 
in tumor cell lines. (Grant and Jarvis, 1996; Reddy et al, 1999). Therefore, these 
findings suggested that interruption of signaling pathways might alter the response to 
chemotherapeutic treatment in tumor cells. 
Recently, many EGFR-targeted cancer therapies have been performed in clinical 
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trials and the outcomes from the cancer patients is encouraging. Targeting signal 
transduction not only has fewer toxic side-effects as traditional therapy, but also can 
be combined with various chemotherapeutic drugs/agents to combat drug resistance in 
a synergistic manner. For example, A431 and MDA-468 xenografts showed enhanced 
anti-tumor responses to doxorubicin and C225 (monoclonal antibody against EGFR). 
(Baselga et al.，1993). In addition, anti-EGFR antibodies ICR-62 and EMD55900 
showed additive effects in combination with cisplatin in human head and neck 
squamous cell lines. {Hoffmann et al, 1997). As a result, understanding more about 
the signal transduction in tumor cells can help development of novel therapies in 
order to modify the efficiency of the current available cancer treatments. 
In the present study, the influences of EGFR signaling modifiers and the 
differential anti-cancer drugs sensitivity between A431 parent cells and 
EGF-conditioned cells were investigated by MTT assay. For methotrexate and 
vincristine sensitivity, it seemed that the differential sensitivity to these drugs in A431 
parent cells and EGF-conditioned cells were not correlated with the alteration of the 
EGFR signaling at all. On the other hand, for taxol sensitivity, although the influences 
were not significantly changed in the presence of the EGFR signaling modifiers 
targeting the Jak/Stat pathway (including Jak inhibitor 1 and Jak2 inhibitor), the 
taxol-mediated resistance in EGF-conditioned cells might be related to the Ras 
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molecules. From Figure 3.25, after the addition of Ras inhibitor — L744832, both 
A431 cells were shown to be more sensitive to taxol. Also, the effects were more 
significantly in EGF-conditioned cells than that in A431 parent cells. As a result, it 
can be postulated that the differential sensitivity to taxol between A431 parent cells 
and EGF-conditioned cells might be associated with the alteration of Ras and its 
downstream signaling transduction. However, all of the recent results are still 
preliminary. More experimental results about the influences of various EGFR 
signaling modifiers targeting different parts of EGFR signaling in combination with 
the ant-cancer drugs are needed so that more novel findings and concrete conclusions 
on the inter-relationship between the differential drug sensitivity and alteration of 
EGFR signaling can be made in the future. 
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Chapter 4 
Identification of Differentially 
Expressed Genes in A431 Parent 
Cells and EGF-conditioned Cells 
by Differential Display (DD) 
4.1 Introduction — Differential Display (DD) 
Differential display (DD) is a very powerful tool for the characterization and 
comparison of gene expression between two or more mRNA populations in various 
conditions. It is a PCR-based method that is developed by Peng Piang and Arthur 
Pardee in 1992. {Liang and Pardee, 1992; Welsh et al, 1992). It has been adopted by 
a large number of laboratories as an important tool that has applications for both in 
vitro and in vivo testing system. {Zimmermann, and Schultz, 1994; Wang et al, 1995). 
To compare with conventional methods for the discovery of differentially expressed 
genes in various conditions, such as substractive library screening or differential 
hybridization method, differential display has several advantages. First of all, it is an 
absolutely simple and rapid method because the majority of experiments are 
performed by PGR. Secondly, only a small amount of RNA from cells is required. 
Thirdly, it can detect genes that are either up-regulated or down-regulated under 
different conditions and allow multiple comparisons between different samples in 
parallel at the same time. Fourthly, it is very sensitive due to the incorporation of 
radioactive a- [^^S]-dATP of the samples during PGR reaction. On the other hand, 
differential display also has a number of limitations. For example, there is a 
significant rate of false positives generation and the labour-intensive nature of the 
procedure for large-scale screening. In addition, those cDNAs fragments identified by 
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differential display are typically small and frequently located in the 3'-untranslated 
region�Thus, additional effort is needed to screen a cDNA library to isolate the Ml 
length of the desired cDNA clone finally. But, many of these limitations have been 
overcome by modification of the differential display protocol nowadays. Therefore, 
differential display is still the most flexible and comprehensive methods available for 
identification of differentially expressed genes in laboratory. It can be used to 
facilitate the discovery of novel targets and understand about the underlying 
molecular mechanisms of cancer pathogenesis. Hence, more effective and tolerable 
cancer therapy can be developed to benefit for cancer patients afterwards. The 
detailed protocol of differential display is described in Figure 4.1. 
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In the previous chapters, experimental results demonstrated that cellular growth 
responses to EGF and sensitivity to various anti-cancer drugs have been changed after 
chronic EGF-conditioning in human squamous camcinoam A431 cells. This might be 
due to the alteration of EGFR signaling in EGF-conditioned cells compared with 
A431 parent cells. However, based on these preliminary data, no definite conclusion 
can be made thoroughly. 
Since the levels of gene expression will vary with time and different 
physiological states in cells, therefore, further investigation of the underlying 
mechanisms about the relationship between differential cellular responses in 
EGF-conditioned cells and the alteration of its signaling are needed. Hence, in this 
chapter, the genes with differentially expression between A431 parent cells and 
EGF-conditioned cells were identified by differential display (DD) method. It is 
possible that some of the genes identified might be associated with the differential 
EGF related growth responses and drug-sensitivity in EGF-conditioned cells. 
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4.3 Materials and Methods 
4.3.1 Materials 
Chemical Company 
> 1 -bromo-3-chloropropane (BCP) Molecular Research Centre 
> Acrylamide / Biacrylamide BIO-RAD 
> Agarose Invitrogen Corporation. 
> Ammonium persulphate Sigma 
> Amplicillin USB 
> Boric acid USB 
> Calcium Chloride Sigma 
> Chloroform BDH Laboratory Supplies 
> Citric acid USB 
> Diethyl pyrocarbonate (DEPC) USB 
> Dulbecco's Modified Eagles's Medium (DMEM) Gibco / Life Technologies, Ltd. 
> EGF Prepotect 
> Ethanol BDH Laboratory Suppliers 
> Ethidium Bromide Sigma 
> Ethylenediaminetetraacetic acid (EDTA) USB 
> Fetal Bovine Serum Gibco / Life Technologies, Ltd. 
> Formaldehyde Sigma 
> Gel extraction kit QIAGEN 
> Gene specific primers Gibco / Life Technologies, Ltd. 
> Glycerol Sigma 
> IPTG USB 
> Isopropanol BDH Laboratory Suppliers 
> LB agar USB 
> L-glutamine Gibco / Life Technologies, Ltd. 
> Magnesium Chloride Sigma 
> Magnesium sulphate Sigma 
> MessageCleam® Kit GenHunter Corp. 
> Mini-preparation kit QIAGEN 
> N,N,N' ,N' -tetramethylethylenediamine (TEMED) BIO-RAD 
> Nylon membrane Amersham Biosciences 
> Oligo-dT primer Gibco / Life Technologies, Ltd. 
> Phenol USB 
> PIPES Sigma 
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> Polyoxyethylenesorbitan monolaurate (Tween 20) Sigma 
> Potassium chloride Sigma 
> QIAEX II gel extraction kit QIAGEN 
> QIAGEN mini-preparation kit QIAGEN 
> Rapid-hyb Buffer Amersham Biosciences 
> Rediprime DNA Labeling System Amersham Biosciences 
> Reverse Transcriptase Gibco / Life Technologies, Ltd. 
> RNA image mRNA differential display system GenHunter Corporation 
> Sodium chloride USB 
> TRI-Reagent Molecular Research Centre 
> Tris-base USB 
> Tryptone USB 
> X-gal USB 
> Yeast extract USB 
Culture Wares Company 
> 60mm and 100 mm culture dishes Coming / Falcon 
> 75cm^ culture flask Coming / Falcon 
> 96-well flat-bottom culture plate Coming / Falcon 
> Microfuge tubes MBP 
Instrument Company 
> Film cassette (with intensify screen) Kodak 
> Filter papers Waterman 
> Microplate Reader Molecular Device 
> Microplate reader Molecular Device 
> Thermal Cycler 9700 Perkin Elmer 
> UV crosslinker UVP 
> X-rays film Kodak / Fuj i 
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4.3.2 Methods 
4.3.2.1 Cell Lines 
In this chapter, except A431 parent cells and EGF-conditioned cells, three 
additional cell lines that were A431 sublines were also employed in the differential 
display experiment. They included the doxorubicin-resistant AlOA cells {Kwok and 
Sutherland, 1991), the cisplatin-resistant CP500N cells and the both cisplatin-resistant 
and EGF-conditioned CP500E cells. Both of them were cultured in Dulbecco 
Modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) 
and 5mM L-glutamine in the humidified 37^C incubator supplied by 10% CO2. 
4.3.2.2 RT~PCR"based mRNA Differential Display 
4,3.2.2,1 Preparation of RNA Samples 
The method and procedures of preparation of RNA samples were mentioned in 
Section 3.3.23.1. But, in order to further eliminate any DNA contamination 
thoroughly from RNA samples, the MessageClean® kit was performed before mRNA 
differential display. It included DNase I digestion, Phenol/Chloroform (3:1) 
Extraction, and Ethanol Precipitation. One point should be ensured that was the whole 
procedures and materials should made with DEPC-H2O before use to free ofRNases. 
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4,3,2.2.2 Identification of Differentially Expressed Genes by RT-PCR 
The RNAimage kit® was employed and the schematic diagram was shown in 
Figure 4.1. First of all, DNA-free 0.1|ig/ml RNA products from A431 cells were 
reverse transcribed by reverse transcription (RT) with MMLV reverse transcriptase, 
dNTP (250|LIM), an anchored oligo dT primer — H-TnA primer (2|LIM). The first 
strand cDNA was amplified was then amplified and radiolabeled with a second short 
arbitrary primer (H-AP45 or H-AP46) (2iaM), dNTP (25|^M), H-TnA and 
a-[35s] dATP by 40 cycles of Polymerase Chain Reaction (PGR). The PGR condition 
was 94�C for 30 seconds, 40^C for 2 minutes and 72�C for 30 seconds and followed 
by 70^C for 5 minutes. After that, the RT-PCR products were run in parallel in 6% 
denaturing polyacrylamide gel. Then, the gel was blotted on a 3M paper and dried 
under vacuum by gel dryer at 80^C for 1 hour. Finally, the differentially expressed 
cDNA pattern could be visualized by exposure of the gel to X-ray film. 
4,3,2.2,3 ReampUfication of cDNA Probes 
According to the signals from X-ray film, those differentially expressed cDNA 
bands between A431 parent cells and EGF-conditioned cells were extracted from the 
3M paper by dissolving it in 3M sodium acetate, lOmg/ml glycogen and 100% 
ethanol. After that, the pellet was then dissolved in water and used for further 
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reamplification afterwards. The cDNAs were reamplified by the same primer set and 
PCR condition except the dNTP concentration was 20|LXM and no radioisotope was 
added this time. Then, the reamplified PCR products were run on a 1.5% agarose gel 
and stained with ethidium bromide. Those PCR products that its size could be 
consistent with that in the differential display gel were extracted from the agarose gel 
by using QIAEX® gel extraction kit. 
4.3.2.2.4 Subcloning of the Differentially Expressed cDNAs 
4.3.2.2..4.1 Preparation of the Ultra-competent E.coli Cells for Transfromation 
Firstly, DH-5a cells were cultured in 4ml SOB medium (including 0.5% yeast 
extract, 2% tryptone, lOmM NaCl, 2，5mM KCl, lOmM MgCh and lOmM 
MgS04-without amplicilin at 37^C overnight followed with vigorous shaking until 
O.D. reached about 0.5. The mixture was kept on ice for 10 minutes. Then, the cells 
could be pelleted by centrifugation at 4000 rpm at for 10 minutes. After that, the 
cells were washed and resuspended by ice-colded TB solution (including lOmM 
PIPES, 15mM CaCl2 and 250mM KCl, pH 6.7). Thus, the E.coli cells were stored at 
-70^C and ready for subsequently transformation. 
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4.3.2.2.4.2 Preparation of Cloning Vector 
Before performing transformation of desired differentially expressed cDNA, 
blunt-ended of pBluescript II SK+ vectors should be needed for following TA cloning. 
First, the vectors were generated by cutting with restriction enzyme --- EcoRV in the 
ratio of 1:1 at 37^C for 1 hour. Then, the linearized vector was mixed with 2mM dTTP 
and Taq DNA polymerase at 72^C for 2 hour in order to generate the T-overhang for 
TA cloning afterwards. After that, the vectors were extracted and precipitated by 
phenol-chloroform (w/v=25:24) and 100% ethanoL The vectors were then 
resuspended in TE buffer. Thus, the vectors were available for the subsequent ligation 
process. 
4.3.2.2..4.3 Transformation 
As mention before, those differentially expressed cDNAs could be ligated into 
the 0.5|il pBS+T vector first for later transformation. The ligation process was carried 
out with T4 DNA ligase at 16^C overnight. Next day, 5|il ligation products were 
transformed in to lOOjil ultra-competent E.coli cells in ice for 5 minutes. After that, 
the mixture was scraped on LB agar plate (with amplicilin) in the presence of 
20mg/ml X-gal and 200mg/ml IPTG and then placed the plate at 37�C overnight. For 
further screening of the desired cDNAs, only white and pale blue bacterial colonies on 
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the LB agar plate could be selected and picked. 
4.3,2,2.5 Verification of cDNA Differentially Expression by Colony-PCR and 
Northern Blot Analysis 
43.2.2.5.1 Colony-PCR 
In order to confirm the expression patterns of those differentially expressed 
cDNAs that were consistent from that in the DD gel, colony-PCR should be 
performed. First, 3-5 white or pale blue bacterial colonies were picked from LB agar 
plates and lysed in 50ml colony lysis buffer (0.1% Tween 20 in Tris-EDTA buffer) by 
boiling for 10 minutes. After centrifugation, the cell debris was pelleted out and the 
supernatant was then collected for subsequent PGR analysis in order to check the size 
of the cDNA insert. The parameters and conditions for PGR were the same as that 
described in previous reamplification. After that, the PGR products were resolved in 
1.2% agarose gel stained with ethidium bromide. Therefore, the sizes of those cDNA 
inserts could be compared with the corresponding reamplified cDNA fragments. 
43.2.2.5.2 Preparation of Cloned Plasmid cDNA and Bacterial Glycerol Stocks 
After checking the corresponding size of cDNA inserts from colony-PCR, the 
single colony from the qualified cDNA inserts was then picked and grown in 4ml 
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SOB medium (with amplicilin) followed with vigorous shaking at 37^C overnight. 
Next day, 1ml bacteria in SOB medium was mixed with 1ml glycerol and then stored 
at -70^C as glycerol stocks for further analysis afterwards. Then, the remaining 3ml of 
bacteria in SOB medium was used for further mini-preparation in order to extract and 
collect the cloned plasmid cDNAby means of the QIAGEN® mini-preparation kit. 
43.2.2.53 Preparation of cDNA Probes for Nothern Blot Analysis 
After the mini-preparation process, 3 ml mini-product with cloned plasmid cDNA 
was amplified by PGR with the same parameters and conditions in colony-PCR and 
then resolved in the 1.2% agarose gel stained with ethidium bromide. After that, the 
gel containing the plasmids were cut and purified by QIAEX® gel extraction kit. 
Then, this plasmid can be used as a probe for subsequent Northern blot analysis 
afterwards. 
4.3.2.2.5.4 Northern Blot Analysis 
First of all, the total RNA of A431 parent cells and its sublines (including AlOA, 
CN, CE and EGF-conditioned cells) were prepared as mentioned in Section 3.3.2.3.1. 
Then, 7[ig of total RNA was collected and run in 1% denaturing formaldehyde 
agarose gel. After that, the RNAs were then transferred onto the nylon membrane 
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overnight. Next day, the membranes were cross-linked by UV light and it is ready for 
further hybridization. 
The purified cDNA probes were hybridized and labeled with [邻]-dCTP by 
employing the Rediprime™ Random prime labeling system. First, the membranes 
were equilibrated in 2X Nucleic acid transfer buffer (SSC) (including sodium chloride 
and citric acid) and pre-hybridized with 10ml hybridization buffer at 65^C for 10-15 
minutes in the hybridization oven. On the other hand, the cDNA probes were first 
diluted to about 20-25 ng with TE buffer in 45jil and then denatured by boiling for 5 
minutes and kept on ice for further 5 minutes. After that, the probes were labeled with 
5ml [32p]-dCTP by Rediprime^^ Random prime labeling system. The mixtures were 
incubated at 37^C for 10 minutes and 5|ji 0.2M EDTA was added in order to stop the 
labeling reaction. The radio-labeled probes were then denatured by boiling for 
5minutes and kept in ice for 5 minutes. So, the radio-labeled cDNA probes could be 
mixed with the hybridization buffer and hybridized with the pre-hybridized 
membranes at 65^C for 2 hour in the hybridization oven. Two hour later, the 
membranes were washed with SDS-containing SSC solution at 65^C for 20 minutes 
once and 15 minutes twice in the hybridization oven. After washing those 
non-specific labeling on the membranes, the expression pattern of mRNA was then 
visualized by exposure to X-ray film with intensifying screen at -70^C for about 1 
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week. 
43.2.2.6 Sequencing of the Desired Cloned cDNA Inserts 
The desired cloned cDNA inserts were sent for sequencing by Techdragon 
company. After that, the resulting sequences were examined and aligned with the 
Genbank database by means of BLAST searching. Through Northern blot analysis, 
the expression pattern of the cloned cDNA inserts in A431 parent cells and its sublines 




In order to investigate any differentially expressed genes or novel genes that may 
be contributed to the differential EGF responses and drug sensitivity between A431 
parent cells and EGF-conditioned cells, their gene expression profiles were further 
studied by mRNA differential display. In the present study, the oligo-dT primer --_ 
H-TiiA (5‘-AAGCTTTTTTTTTTTA-3') were employed in combination with two 
13-mer arbitrary primers, including H-AP45 (5‘-AAGCTTGGCTGAC-3‘) and 
H-AP46 (5，-AAGCTTCGGTCCT-3') respectively for RT-PCR reactions. After the 
denaturing polyacrylamide gel electrophoresis, the gene expression profiles between 
A431 parent ceils and EGF-conditioned cells were demonstrated and visualized by 
autoradiography. The experimental results were shown in Figure 4,2. 
For arbitrary primer — H-AP45, there were 20 bands in total that showed 
significantly differential expression between A431 parent cells and EGF-conditioned 
cells in DNA sequencing. As shown in Figure 4,3 (a), 9 (no. 1-9) of them could be 
reamplified successfully by subsequent PGR reaction. After that, 6 of them were able 
to be subcloned into the pBluescript vector and further confirmed their sizes by 
colony-PCR afterwards. Then, all of them have been subjected to DNA sequencing 
and the desired sequences were then aligned with the Genbank database by means of 
BLAST searching. But, the verification of the differentially expression of those 
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desired clones still has not been performed by Northern blot analysis, therefore, it 
needs further confirmation in the future before characterization of those potential 
clones. 
For another arbitrary primer --- H-AP46, there were 12 bands in total that 
showed significantly differential expression in A431 parent cells and 
EGF-conditioned cells. As shown in Figure 4,3 (b), 5 (no.11-15) of them could be 
reamplified successfully afterwards. So, these 5 clones were subcloned into the 
pBluescript vector and their sizes were confirmed from that shown in the 
reamplification results by colony-PCR. All of them have been subjected to DNA 
sequencing and were aligned with respect to the Genbank database by BLAST 
searching. In addition, all of them have also been prepared as cDNA probe for further 
verification by Northern blot analysis. However, only 2 clones (no. 11 & 12) could be 
successfully confirmed. The results were shown in Figure 4.4. After DNA sequencing 
of two desired cDNA clones, it indicated that two of them were known genes. 
Moreover, they possess various cellular functions in cells. The results of Blast search 
were shown in Figure 4,5 and summarized in Table 4,1. One of them represents 
mitochondria proteins and another refers to ribosomal protein. These genes might be 
chosen for further identification of their roles in contribution to differential EGF 
responses and drug sensitivity in EGF-conditioned cells compared with A431 parent 
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cells as mentioned in the previous chapters. 
From the above experimental results, it indicated that not all of the clones can be 
successfully identified eventually. As mention before, it might be mainly due to the 
false-positive results induced from differential display experiment or there were no 
signals detected by Northern blot analysis as well. 
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M H-AP45 arbitrary primer (b) H-AP46 arbitrary primer 
(5‘-AAGCTTGGCTGAC-3‘) (5, -AAGCTTCGGTCCT-3') 
AP 10 N E AC AP 10 N E AC 
Mi 
： 一 • 讓 ‘ 
編 纖 秦 - ‘ 膠 料 ： 
6 . • m A ^ lam j 緣警《'赞 
• 拳 • fell ： 酵 - m 漏 _ _ _ 
考 * • 崎 _ 救 騰 藤 麵 
Figure 4.2 (a) & (b). The gene expression profiles in A431 cells performed by differential display. 
First of all, mRNA from A431 cells were reversed transcribed to single-stranded 
cDNA by using an one-based anchored oligo-dT primer --- H-TnA. Then, 
cDNAs were amplified by PGR with the combination of the same oligo-dT 
primer as used for the reversed transcription and an arbitrary primers (including 
H-AP45 and H-AP46 respectively).After that, the differentially expressed genes 
between A431 parent cells and EGF-conditioned were separated and compared 
in 6% polyacrylamide gel electrophoresis and then visualized by 
autoradiography afterwards. "AP" refers to A431 parent cells; “10” refers to 
doxombicin-resistant A431 cells; "N" refers to cisplatin-resistant A431 cells; “F, 
refers to both doxorubicin and EGF-resistant A431 cells; "AC" refers to 
EGF-conditioned A431 cells. The indicated numbers refer to the differentially 
expressed genes that could be reamplified afterwards. 
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a^) H-AP45 arbitrary primer 
Band no. 1 2 3 4 5 6 7 8 9 M 
小、H-AP46 arbitrary primer 
Band no. 11 12 13 14 15 M 
Figure 4.3 (a) & (b). Reamplification of the differentially expressed bands extracted 
from differential display gels. Differentially expressed cDNA 
fragments were extracted and further reamplified by PCR with the 
same primer sets and PCR conditions. After that, the reamplified 
cDNAs were resolved in 1.2% agarose gel. So, the corresponding 
sizes in reamplification of the cDNA fragments could be verified 
from that in the DNA sequencing gels. M refers to lOObp DNA 
ladder marker. The numbers represents the cDNAs that have been 
chosen for further cloning experiment. 
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("a) H-AP45 arbitrary primer 
K P - 4 6 - 6 ( n o . 1 1 ) ^ ^ AC： 
1 8 S r R N A 
H-AP46 arbitrary primer 
K P - 4 6 - 7 ( n o . 1 2 ) A P A C 
‘ srfv-r-Tf : : : •^广 r “^―； ，，― 
2 8 S r R N A A P A C 
1 8 S r R N A 
Figure 4.4 (a) & (fo). Northern Blot analysis of cDNA clones identified from differential 
display. The two differentially expressed cDNA fragments were 
reamplifed and subcloned into the pBluescript vectors. Then, the positive 
clones (white colonies) were picked for subsequent confirmation by 
colony-PCR and resolved in 1.2% agarose gel. After that, the cDNA 
inserts with consistent sizes compared with reamplified results from 
Figure 4.3 were then purified by QIAEX gel extraction kit and 
radiolabeled with [ P-dCTP] by Redprime II random prime labeling 
system. lOug RNA from A431 parent cells and EGF-conditioned cells on 
nylon membrane were than hybridized with the desired cDNA probes in 
order to further verify the expression patterns found in differentially 
display. Finally, the size of the desired gene could then estimated by the 
relative distance with respect to the 18S and 28S rRNA on the same blot. 
AP refers to A431 parent cells and AC refers to EGF-conditioned cells. 
The expression levels of 18S and 28S rRNA were used to ensure the equal 
loading of the samples. 
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Blast search result: 
S e q u e n c e s p r o d u c i n g s i g n i f i c a n t a l i g n m e n t s : S c o r e ( b i t s ) E v a l u e 
gi I 4 8 5 9 6 1 7 7 | gb | A Y l 9 5 7 6 9 . 2 | H o m o s a p i e n s h a p l o t y p e E 2 2 i m i t o . . .436 e - 1 2 0 
giI 1 7 9 8 5 7 3 9 | g b | A F 3 8 2 0 0 7 . 1 | H o m o s a p i e n s h a p l o t y p e 工 m i t o c h o . . .436 e - 1 2 0 
D 
giI 3 2 8 9 3 8 0 7 | g b | A Y 3 3 9 5 0 9 . 1 | H o m o s a p i e n s i s o l a t e F108 (PS66) . . .436 e - 1 2 0 
H 
giI 3 2 8 9 3 7 9 3 | g b | A Y 3 3 9 5 0 8 . 1 | H o m o s a p i e n s i s o l a t e F107 (PS83) . • .436 e - 1 2 0 
圃 
giI 3 2 8 9 3 7 7 9 | g b | A Y 3 3 9 5 0 7 . 1 | H o m o s a p i e n s i s o l a t e F106 (PS81) . . .436 e - 1 2 0 
鼴 
giI 3 2 8 9 3 7 6 5 | g b | A Y 3 3 9 5 0 6 . 1 | H o m o s a p i e n s i s o l a t e F105 (PS76) ...436 e - 1 2 0 
圔 
qiI 32 8 937 51 Igb|AY33 9505.1| H o m o s a p i e n s i s o l a t e F104 (PK4 2) . . .436 e - 1 2 0 
m 
g i | 3 2 8 9 3 7 3 7 | g b | A Y 3 3 95 0 4.1| Homo s a p i e n s i s o l a t e F103 (PS89) . • .436 e - 1 2 0 
圃 
giI 3 2 8 9 3 7 2 3 | g b | A Y 3 3 9 5 0 3 . 1 I H o m o sapiens i s o l a t e F102 (PS80) . . .436 e - 1 2 0 
D 
g i 1 3 2 8 9 3 7 0 9 1 g b I A Y 3 3 95 02.1 I Homo s a p i e n s i s o l a t e FlOl (PS58) . . .436 e - 1 2 0 
國 
gi I 3 2 8 9 3 6 9 5 | gb | A Y 3 3 9 ^  ' . 1 | Homo s a p i e n s i s o l a t e FlOO ( PL60 ) . . .436 e - 1 2 0 
D 
gi 1328936811 gb I A Y 3 3 9. . ^  Homo sapiens isolate F99 (PL83) . . . 436 e-120 
圃 
gi I 32893667 | gb | A Y 3 3 9 4 99 . 1 I Homo sapiens isolate F98 (PL81) . . .436 e-120 
圃 
g i 1 3 2 8 9 3 6 5 3 1 g b I A Y 3 3 94 98.1 I Homo sapiens isolate F97 (PL57) . . . 436 e-120 
D 
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g i I 328 93 63 9 I g b | A Y 3 3 94 97 . 1 | H o m o s a p i e n s i s o l a t e F96 (PL2 6) . . .436 e - 1 2 0 
D 






Blast search result: 
S e q u e n c e s p r o d u c i n g s i g n i f i c a n t a l i g n m e n t s : S c o r e (bits) E v a l u e 
giI 2 7 4 3 6 9 4 1 | r e f | N M 0 0 2 9 5 4 . 3 1 H o m o s a p i e n s r i b o s o m a l p r o t e i n . . .389 e - 1 0 5 
H Q Q 
gi|4254265〇|gb丨 B C 0 6 62 93.1| H o m o s a p i e n s r i b o s o m a l p r o t e i n S . • . 389 e - 1 0 5 
D m 
g i | 3 4 7 8 3 0 9 4 | g b | B C 0 0 1 3 92 . 2 | H o m o s a p i e n s r i b o s o m a l p r o t e i n S . • . 389 e - 1 0 5 
B 函 
g i 丨 3 1 4 1 9 7 32 I gb I B C 0 5 3 3 7 1 . 1 丨 H o m o s a p i e n s r i b o s o m a l p r o t e i n S . . . 389 e - 1 0 5 
DEI 
q-i 丨 34 52 6 68 6 I dbj j A K 1 2 9 9 7 2 . 1 | H o m o s a p i e n s c D N A F L J 2 6 4 6 2 f i s , . . . 389 e - 1 0 5 
H 
giI 5 0 5 0 6 7 9 6 | e m b | C R 6 2 5 9 8 9 . 1 I f u l l - l e n g t h c D N A c l o n e C S 0 D I 0 7 4 . . .389 e - 1 0 5 
gi丨50485331 I e m b | C R 6 0 4 52 4.1丨 f u l l - l e n g t h c D N A c l o n e C S 0 D C 0 2 5 . . .389 e - 1 0 5 
giI 5 0 4 8 2 0 7 9 I e m b | C R 6 Q 1 2 7 2 . 1 | f u l l - l e n g t h c D N A c l o n e C S 0 D E 0 0 8 . . . 389 e - 1 0 5 
g i I 2 4 3 8 8 7 1 g b | S 7 9 5 2 2 . 1 | S 7 9 5 2 2 u b i q u i t i n c a r b o x y l e x t e n s i o n p . . . 38 9 e - 1 0 5 
mm 
gi|3757Q|emb|X63237.1|HSUBA8QR H.sapiens UbaSO mRNA for u b i … 3 8 9 e-105 
圜 
Figure 4.5. The sequences and the blast search results of the desired two clones, 
including KP-46-6 (no.ll) and KP-46-7 (no.l2). 
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Sizes of 
Number of Name of Estimated Homology of the ^ . 
…，Express ion cDNAs . ^ � • � Accession 
cDNA cDNA size of genes desired gene 
1 1 pattern from DD , … … no. 
clones clones from NB(bp) sequence  
gel(bp)  
Homo sapiens 
11 KP-46-6 AP>AC 200 1250 haplotype E22i AY195769 
mitochondria  
Homo sapiens 
12 KP-46-7 AP> AC 232 2834 ribosomal protein NM002954 
S27a  
Table 4.1. Summary of differentially expressed cDNA cloned and sequenced by 
alignment with the Genbank database by BLAST in A431 parent cells and 
EGF-conditioned cells. NB refers to Northern Blot analysis, AP refers to A431 
parent cells and AC refers to EGF-conditioned cells. 
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4.4 Discussion 
In order to try to explore the novel aspects contributed to the differential EGF 
responses and drug sensitivity by chronic EGF-conditioning in A431 parent cells and 
EGF-conditioned cells, differential display was employed. It is a very powerful and 
simple method for comparison of gene expression profile between two or more 
mRNA populations under different conditions. Therefore, novel molecular targets 
might be found for further identification of the inter-relationship between differential 
EGF responses and drug sensitivity and EGF-conditioning. 
In the present study, two desired clones, including KP-46-6 and KP-46-7 have 
been successMly verified and sequenced finally and they were mitochondria gene 
and ribosomal protein respectively. According to many scientific literature reviews, it 
can show that these two genes are closely related to anti-cancer drugs sensitivity. For 
KP-46-6, as we all know that mitochondria is a very important regulator during 
apoptosis. Therefore, it can be considered as a potential anti-cancer target for cancer 
therapy. For example, oligomycin that is a mitochondria inhibitor can block Pgp 
activity and elicit DNA fragmentation in cancer cells. {Li et al, 2004). On the contrary, 
for KP-46-7, ribosomal proteins play crucial roles in many cellular processes, 
especially translation. Thus, ribosomal proteins may have the ability to alter the drug 
sensitivity by modifying the synthesis and expression of some drug sensitivity related 
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genes or proteins. For instance, elevated expression of S3a ribosomal protein can 
increase the drug sensitivity in tumor cells. (Hu et al” 2000) 
Although differential display has many advantages and it can really help 
researchers to explore novel genes as well, it is not an easy task to clone and verify 
the desired clones successfully at the end. According to the experimental results, by 
using the arbitrary primer — H-AP46, it had 5 clones that could be successfully 
reamplified by PGR originally. However, there were only 2 clones could be firmly 
verified and sequenced consequently. 
In fact, there are a number of other technologies for studying the gene expression 
profiles in cells under different physiological states. cDNA microarray is a good 
example. In the future, gene expression profiles between A431 parent cells and 
EGF-conditioned cells may be performed by other experimental methods as well so 
that novel genes conferring the differential EGF responses and drug sensitivity by 
EGF-conditioning can be explore at another aspects molecular levels, too. 
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Chapter 5 
General Conclusion and Future 
Perspectives 
5.1 General Conclusion 
EGFR-targeting therapy is a recent and potential direction in cancer therapy. It is 
mainly because it is less toxic and has mild side-effect than the traditional 
chemotherapy and radiotherapy. EGFR signaling is an extremely complicated network 
and it is comprised of multiple downstream signal transduction pathways. But, the 
potential molecules that demonstrated the most therapeutic effective involved in 
EGFR signaling are still not fully understood. 
In the present study, the differential EGF related growth responses were observed 
in A431 parent cells and EGF-conditioned cells. EGF suppresses the growth of A431 
parent cells but stimulates that of EGF-conditioned cells. Moreover, the expression 
levels of a number of signaling molecules in three major EGFR signaling pathways, 
including the Ras/Raf/MAPK pathway, the Jak/Stat pathway and the PBK/Akt 
pathway, were also compared in these two cell lines. Since the expression levels of 
PI3K in A431 parent cells and EGF-conditioned cells seemed to be similar so that the 
PBKyAkt pathway might not be participated in the alteration of EGFR signaling. 
Thus, the following experiments focused on the Ras/Raf/MAPK pathway and the 
Jak/Stat pathway instead. Interestingly, for the Ras/Raf/MAPK pathway, the 
expression levels of most signaling molecules were higher in A431 parent cells than 
EGF-conditioned cells; but for the Jak/Stat pathway, EGF-conditioned cells had a 
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higher expression level. Therefore, it is believed that the downstream EGFR signal 
transduction pathway is really varied in EGF-conditioned cells. 
Recently, many reports indicated that EGFR-targeting therapy can potentiate the 
rational chemotherapy and radiotherapy by enhancing their anti-tumor activity. Hence, 
the differential sensitivity to several anti-cancer drugs, including camptothecin, 
methotrexate, 5-flurouracil, vincristeine and taxol were examined. EGF-conditioned 
cells were shown to be more resistant to camptothecin, methotrexate, vincristine and 
taxol, but became more sensitive to 5-fluorouraciL The underlying mechanisms were 
also investigated by examining the expression levels of their related drug resistance 
factors between A431 parent cells and EGF-conditioned cells. Apart from this, the 
differential drug sensitivity in these two cell lines might be due to the alteration of 
EGFR signaling in EGF-conditioned cells and such inter-relationship was also studied 
by examining the influence of EGFR signaling modifiers on differential drug 
sensitivity in these two cell lines. 
In fact, based on all the experimental results, a hypothesis can be proposed to try 
to explain the relationship between the differential EGF related growth responses or 
drug sensitivity and the alteration of EGFR signaling in EGF-conditioned cells. 
Theoretically, after the ligand (EGF) binding to EGFR, it can trigger a cascade of 
phosphorylation to activate multiple signal transduction pathways so that various 
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cellular responses can be induced. Under normal physiological condition, the 
Ras/Raf/MAPK pathway and the Jak/Stat pathway somehow crosstalk with each other 
and they may be existed in an equilibrium status. The responsibility of these two 
signaling pathways is totally different. The Ras/Raf/MAPK pathway will likely be 
responsible for the EGF suppression growth and makes the cells become more 
sensitive to anti-cancer drugs; and the Jak/Stat pathway might predominantly be 
responsible for cell growth stimulation by EGF and make the cells become more 
resistant to drugs. However, chronic EGF-conditioning treatment may alter the 
expression of the signaling molecules in these two EGFR signal transduction 
pathways. After EGF-conditioning, the cells may predominantly have higher 
expression of molecules in the Jak/Stat pathway rather than those in the 
Ras/Raf/MAPK pathway. As a result, the EGF-conditioned cells will then likely be 
stimulated by EGF and shown to be more resistant to most of the anti-cancer drugs. 
The mechanisms or factors that contribute to this alteration of signaling pathway are 
yet to be identified. Further investigation and characterization is needed in the future. 
If such correlation can be declared, it is believed that it must help scientists to 
understand more about the underlying EGFR signaling and modulate the currently 
available EGFR-targeted cancer therapy so that it can more effectively cure the tumor 
cells. 
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5.2 Future Perspectives 
As mentioned before, it is important to further investigate the effect of 
prolonged EGF-conditioning treatment of cells on the alteration of expression in the 
Ras/Raf/MAPK pathway and the Jak/Stat pathway. Then, the inter-relationship 
between the differential EGF related growth responses / drug sensitivity and the 
alteration of EGFR signaling can then be explored clearly. 
First of all, for the differential EGF related growth responses, the expression 
levels of particular signaling molecules and its respective phosphorylated formed after 
the treatment of specific signaling modifiers in combination with EGF in A431 parent 
cells is needed. It can be used to further confirm whether the difference in EGF 
growth responses between A431 parent cells and EGF conditioned cells is associated 
with the shifting of EGFR signaling pathway. 
Secondly, after the clarification of chronic EGF-conditioning on EGFR 
signaling shifting, it is interesting to study about the duration of EGF-conditioning 
needed. In the present study, the EGF-conditioned cells were incubated with 50ng/ml 
EGF for 30 weeks. But, a shorter EGF-conditioning might already be enough to 
contribute to the EGFR signaling shifting in tumor cells. In order to study such aspect, 
the expression levels of EGFR signaling components in the presence of EGF at 
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different time points can be performed. 
Thirdly, for the differential drug sensitivity, more experiments is needed about 
the influence of EGFR signaling modifiers on the effect of drug sensitivity in A431 
parent cells and EGF-conditioned cells 
Finally, in order to explore some novel molecular targets contributed to the 
alteration of EGFR signaling in EGF-conditioned cells as compared with A431 parent 
cells, differential display can be employed. Differential display (DD) is a powerful 
tool for identification of gene expression in different mRNA populations in various 
conditions. By using such method, differential expression of novel genes in A431 
parent cells and EGF-conditioned cells can then be chosen for further identification 
about the inter-relationship between the differential EGF growth responses or drug 
sensitivity and the alteration of EGFR signaling at molecular level. 
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